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Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic disease that mainly affects 
the synovial joints, but may also have extra-articular manifestations. The prevalence in t he 
general adult popu lation is between 0.3-1%. Although the disease can occur at any age, 
most patients are between 40-60 years. Women are more frequently affected than men. 1;2 
Most patients have a symmetric polyarthritis, characteristically affecting metacarpo-
phalangeal (MCP), proximal inter-phalangeal (PIP) and metatarso-phalangeal (MTP) joints. 
This polyarthritis causes joint swelling and pain and subsequent loss of functiona l abi lity. 
If the disease is left untreated, it can lead to further disability, progressive joint destruction 
and loss of quality of life. In addition, high disease activity is associated with - amongst 
others - increased risk for infections and cardiovascular events2 ·4 Thus, treatment of 
RA should be aimed at reducing pain and swelling at time of inflammation, but also at 
preventing joint destruction and permanent loss of function in the future. 
TREATMENT OPTIONS AND STRATEGY 
During the last decades, RA treatment has changed considerably, both in treatment options 
and in treatment strategies. Previously, RA treatment comprised main ly Non-Steroidal Anti 
Inflammatory Drugs (NSAIDs), Disease Modifying Anti-Rheumatic Drugs (DMARDs) and 
glucocorticoids. Recent advances in the understanding of the pathogenesis of RA have led 
to the identification of cellular and molecular therapeutic tar~Jets. Anti-Tumour Necrosis 
Factor-alpha (TNF-a) blocking agents were among some of the first biologic agents to be 
investigated in RAs One of these TNF-blockers is infliximab, which is a chimeric (h uman-
mouse) monoclonal antibody to human TNF-a, and was the first to be proven effective in 
established and early RA in several studies6 ·8 
Treatment strategies also changed fundamentally; where a gradual step-up regimen 
starting with NSAIDs and followed by DMARDs used to be standard practice, a more 
aggressive strategy is advocated nowadays. Pivotal in this new strategy is to treat as early 
as possible in the disease course (hit early) and to reach low disease activity as soon as 
possible by using a combination therapy of several DMARDs including glucocorticoids and 
if necessary biologies (hit hard) 9 Several studies have demonstrated that there is a clear 
correlation between reaching low disease activity or remission early and rapidly in the disease 
course and less joint destruction.10-12 A prerequisite for the "hit hard and hit early" strategy 
is the combination of this strategy with intensive monitoring of disease activity, setting 
goals and adjusting therapy if the goal is not reached (treat to target) . This "treat to target" 
principle has been widely investigated and each time it has prove·d to be more effective than 
routine outpatients care, resulting in low disease activity or even remission in the majority of 
patients, prevention of joint damage and better function and quality of lifeB-19 
There are several instruments to measure disease activity. One of these instruments is 
the Disease Activity Score 28 (DAS28). lt is a validated and frequently used tool in both 
medical studies and daily clinical practice. The DAS28 is a composite score based on the 
number of tender and swollen joints (of 28 joints), the Erythrocyte Sedimentation Rate 
(ESR) and patient's global assessment of disease activity or general health on a 100 mm 
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visual analogue scale (VAS). On the basis of validated cut off points, DAS28 scores can be 
categorized into different levels of disease activity ranging from remission, low, moderate 
to high disease activity. In addition, DAS28-based response criteria to assess whether 
treatment is effective have been developed.20·22 
A downside of the DAS28 for use in daily clinical practice is the time-consuming ESR 
measurement. Originally, the DAS28 has been validated using the Westergren method to 
determine ESR. 23 To perform this test. anti-coagulated blood is placed in an upright tube, 
known as a Westergren tube, and the rate at which the erythrocytes fal l is measured 
and reported in mill imeters per hour. By definition, it takes at least 60 minutes time and 
this hampers the use of the DAS28 in daily practice. One of the options to expedite the 
DAS28 measurement would be to use automated rapid ESR analysers, which have become 
available on wide scale during the last years. Some of these analysers have extrapolation 
algorithms and alternative measurement approaches, and can give an estimation of the 
ESR within three minutes24-26 Unfortunately, the DAS28 has not been validated w ith these 
ESR analysers and the use of these methods could induce misclassification . 
OVERTREATMENT 
An important disadvantage of the "treat to target" compared to traditional "step up" 
approach, is that the former does not allow for individual titration of the minimal effective 
treatment. When the dose is gradually increased ("step up" approach) until a low disease 
activity state is met, overtreatment is largely prevented. lt will, however, result in a high(er) 
disease activity in the beginning of the disease as a consequence. To prevent overtreatment 
caused by the "hit early, hit hard," along with "treat-to-target" strategy, treatment should be 
pro-actively tapered in patients with stable low disease activity, up to the point that either the 
disease activity increases or medication can be stopped. This way, the minimal effective dose 
is found and overtreatment is prevented. One can therefore argue that the paradigms "hit 
early, hit hard" and "treat-to-target" should thus be amended with "how low can you go". 
Since higher dosages of TNF-blockers, like infliximab, are associated with a higher 
risk for - dose dependent - adverse effects (infections, malignancies like non-melanotic 
skin cancer) and with higher cost (in the Netherlands 1 year of treatment with infliximab 
3mg/kg every 8 weeks costs 9000- 12,000 Euro in medication costs), dose reduction 
strategies seem appealingn-32 However, active dose reduction in RA patients that are 
doing well on biologies is not widely adopted by rheumatoloqists in cl inical practice, as 
examplified by relatively high median anti-TNF dosages in biologic registries33'34 This has 
several causes. Firstly, an important prerequisite for the approach "how low can you go " 
is, equal to the "treat to target" strategy, that frequent monitoring of disease activity 
is necessary. Unfortunately, this prerequisite is often not met in daily clinical practice 35 
Secondly, rheumatologists - and presumambly patients too - are generally re luctant to 
change treatment, let alone change "a winning team" 36 Let's examine this further. 
When a patient starts a biologic and low disease activity is reached, the most common 
action taken by the rheumatologist is not changing medication as it is concluded that the 
patient must be responding to the treatment. However, the relation between the (dose 
of) medication and improvement in disease activity is more complicated than a simple 
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cause-effect relation: two alternative scenario's are possible. Firstly, the patient would have 
responded on a lower dose (the dose is a supratherapeutic dose) or, secondly, the patient 
would also have improved even without medication (the dose/drug is nontherapeutic). 
This last well-established phenomenon ca lled spontaneous improvement or "regression to 
the mean" is often not recognised, but is seen in 20-40% of the placebo treated patie·nts 
in RCT'sJ7 This improvement is not only caused by placebo effect (expectation bias) but 
also to a large extent by regression to the mean. 37-39 
The solution to this problem of overtreatment - which will inevitably increase when 
more intensive multidrug strategies find their way in clinical practice - is consistent and 
regular measurement of disease activity, lowering the dose of the drug in case of low 
disease activity and either increasing the dose when a flare in disease activity occurs or 
stopping medication completely if low disease activity remains. When implementing lthis 
proactive dose reduction, a problem arises; no validated flare criterion is avalaible . Since 
the DAS28 is a frequently used instrument to measure disease activity in daily clinical 
practice and it also has validated response criteria and disease activity states, it would be 
valuable to also have a validated DAS28-based f lare criterion.20-22 
DOWN-TITRATION AND DISCONTINUATION OF TREATMENT 
Dose reduction of TNF-blockers has been shown to be feasible, mostly in patients receiving 
higher than registered doses. Den Broeder et al demonstrated that DAS28 guided down-
titration of adalimumab in RA patients was feasible in 71% of the patients. Most patie·nts 
were treated with higher than registered doses. In addition, Van den Bemt et al down-
titrated RA patient treated with infliximab 5mg/kg to 3 mg/kg . In the majority of the patients 
(89%) this did not resu lt in a f lare of the disease. Both studies demonstrated a sizable 
reduction in dosage without persistent increase in disease activity in nearly all patients.-~0;4 1 
Discontinuation of TNF-blockers in RA patients with low disease activity has also been 
investigated . In the BeSt study (BeSt stands for a Dutch acronym Behandel Strategieen 
which means treatment strategies), recently diagnosed RA patients were randomised to 
different treatment arms with one of the arms being infliximab combined with methotrexate 
as a f irst line treatment. In patients with stable RA remission for at least 6 months infliximab 
was discontinued. Both the one- and two years results demonstrated that about 50% 
of the patients remained in remission.11;42 In a Japanese study established RA patie·nts 
treated with infliximab were included. All patients had to have failed to methotrexate 
mono-therapy or combined with another DMARD prior to infliximab initiation . lnfliximab 
then was discontinued if patients had a DAS28 of less than 3.2 (low disease activity) for at 
least 24 weeks. Also in this study approximately 50% remained having low disease activity 
after discontinuing TNF-blocker treatment43 However, overal l data is still limited on down-
titration and discontinuation of TNF-blockers in RA patients with long term low disease 
activity, nor is clear what the consequences are with regard to cost-effectiveness. 
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THERAPEUTIC DRUG MONITORING 
One drawback of widespread use of trial-and-error dose down-titration strategies that 
remains, is the temporarily flare in disease activity that by definition w ill occur in all patients, 
except the patients that can eventually stop the TNF-blocker. This flare will temporari ly 
affect the quality of life of the patient, but is possibly also associated with more rad iological 
damage44;45 Prediction of which patient can reduce the dose and which cannot could prevent 
these flares. Also, identification of patients in whom TNF-blockers can be discontinued 
would prevent a time consuming down-titration period, as the drug can be stopped directly. 
A promising solution is the use of therapeutic drug monitoring (TOM). Measuring 
serum trough levels of TNF-blockers and even antibodies formed against these drugs 
might aid in identifying which patient s can partly down-titrate or discontinue anti-TNF-
treatment. Succesful appl ication of TOM however has some prerequisites; (1) a valid and 
reliable drug assay needs to be avai lable, (2) a large variation in both serum levels and 
the outcome that is to be predicted has to be present, (3) a clear association has to exist 
between drug levels and future clinical outcome, (4) the therapeutic effect cannot be 
easily and completely measured by clin ical observation or other easy and feasible tests 
and (5) a small range in therapeutic dosages (limited either by toxicity or costs) has to be 
present.46 In addition any test should have clinical or therapeutic consequences (6) and 
ideally administering the test has to be cost-effective (7). 
W ith regard to the first prerequisite: a validated and accessible drug assay is 
available 4 7;48 The second and third prerequisites have been demonstrated in inception 
cohorts of RA patient s starting on infliximab. In these cohorts infliximab serum trough 
levels or anti-infliximab-antibodies were correlated with future clinical effect.47-52 However, 
in long term treated RA patients this is less well known . Additionally, exact and val idated 
cut-off va lues f or serum trough levels to determine which levels are considered ineffective 
or therapeutic are unknown. The fourth and fifth prerequisites also aply when considering 
down-titration and discontinuation of TNF-blockers: so far no other clinical observations 
or tests can predict succesful down-titration/discontinuation, and dose related toxicity and 
costs are clear. Thusfar, however, TOM has not been used in RA in clinical practice and 
up till now no study has demonstrated that adding TOM guided treatment to "treat to 
target" is a superior strategy than the latter alone. This is because the test characteristics 
(cutt-off threshold, sensitivity and specificity) of biological serum levels to predict succesful 
down-titration have not been established. 
AIM AND OUTLINE OF THIS THESIS 
Treating RA patients according to the "hit early, hit hard" and "treat to target" parad igms 
is more effective than routine care, but can lead to overtreatment. To prevent this, the 
paradigm "how low can you go" after stable low disease activity is reached could be 
valuable. Overall, this thesis aims at increasing the knowledge on whether this is the case 
and how this can be reached. 
To investigate whether lowering or discontinuing infliximab dose is possible, several 
boundary conditions have to be met. First, a valid flare criterion is necessary, which is 
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ideally based on the instrument used to measure disease activity in daily clinical practice 
and readily available as the patient visits the outpatient clinic, I ike the DAS28. Due to the 
ESR measurement the DAS28 costs time. Since rapid ESR analysers are widely available 
they could optimise RA care. However, it has to be verified whether DAS28 calculations 
based on the results of these analysers are not causing misclassification of patients w ith 
subsequent incorrect treatment decisions. The outcome of this verification is described in 
chapter 2.1 . In addition, although the DAS28, the DAS28-base•d response criteria and the 
separate disease activity states have been validated, there is up till now no valid DAS28 
flare criterion. In chapter 2.2 the construct and criterion validity of several DAS28-based 
flare criteria are described. 
In chapter 3 of this thesis the feasibility of down-titration or even discontinuation of 
infliximab in long term treated RA patients with long term stable low disease activity is 
described. In addition the effect of infliximab down-titration on costs and quality of life 
was determined. Of course the effect on costs will be largely influenced by the reduction 
in infliximab, however unwarranted flares during down-titration might cause significant 
loss of quality of life and might even induce extra costs due to extra outpatient cli nic visits, 
work related absenteeism and extra medication to regain disease activity control. 
Ideally, only in the patients who are treated with a higher dose than they need 
(supratherapeutic dose) or the patients who do not (or no longer) need treatment w ith 
TNF-blockade (nontherapeutic dose) the infliximab dose is down-titrated or discontinued 
respectively. To examine if measuring infliximab serum trough levels and anti-infl iximab 
antibodies could be useful to predict this, first reliability and presence of a large variation 
in the serum levels in patients with stable low disease activity had to be confirmed 
(chapter 4.1). In chapter 4.2 sensitivity and specificity analyses of different serum trough 
level categories (low, normal, high) and anti-infliximab-antibodies at baseline are described 
for the prediction of successful infliximab down-titration or discontinuation. 
Finally, in chapter 5 all our results are summarised and a ge111 eral discussion is provided 
on the consequences of our findings. Also clinical recommendations and proposit ions for 
future research are proposed. 
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Monitoring of disease activity using DAS28 is more effective than routine RA care, but the 
ESR measurement is time consuming. Alternative rapid ESR determination methods can be 
used but effects on DAS28 classification are unknown. 
Methods 
Alternative rapid ESR methods, including the Starrsed 30 minute mode and Alifax Rol ler 
Test-1TH, were compared to the Westergren method. Mean difference, limit s of agreement 
(LoA) and intraclass correlation coefficients (ICC) were calculated. Based on these results, 
using a longitudinal design the percentage of DAS28 misclassification for the Alifax Roller 
Test-1TH was measured. 
Results 
The Alifax showed acceptable ICC's, but LoA were large. ICC was 0.67 (0.56-0.76), 
LoA -43;34 . The longitudinal study on the Alifax (n= 125) showed an ICC of 0.93, a kappa 
of 0.61, but disease activity was misclassified in 26% of the patients. Use of the ESR from 
the previous visit resulted in comparable levels of misclassification 
Conclusion 
ESR measured by automated analysers like A lifax show acceptable ICC but LoA are large 
compared to the Westergren ESR. The Alifax Roller Test-1TH is very rapid but DAS28 
misclassification is considerable and even as large as when using the ESR of the previous visit 
DAS28 misclassification due to different methods for rapid ESR determination 
INTRODUCTION 
Intensive monitoring of disease activity in patients with rheumatoid arthritis (RA) includ ing 
?settings goals and adjusting therapy accordingly have proved to be more effective than 
routine outpatients care. 1•4 The Disease Activity Score 28 (DAS28) is a validated and frequently 
used tool to monitor disease activitys-5 it is a composite score based on the number of tender 
and swollen joints (of 28 joints), the Erythrocyte Sedimentation Rate (ESR) and patient's global 
assessment of disease activity or general health on a 100 mm visual analogue scale (VAS).5 On 
the basis of validated cut-off points DAS28 scores can be categorized into different levels of 
disease activity (ranging from remission, low, moderate and high disease activity)s-s 
Originally the DAS28 has been validated using the Westergren method, which takes 
at least 60 minutes time.9 This hampers the use of the DAS28 in daily pract ice. SevE?ral 
options can be considered to reduce the time needed to determine DAS28. First of all, 
automated rapid ESR analysers are available. These analysers provide an estimation of t he 
Westergren ESR either by extrapolating from a shorter sedimentation time (f or example 
ESR measured by St arrsed in 30 minute mode) or measure the ESR in a different method, 
for example by means of density measurement with infrared reading of the dynamics of 
erythrocytes (for example Alifax Roller Test-1TH). Other options include the use of the 
ESR of the previous visit, which is f requently done when the current ESR is missing, or 
ask patients to come for ESR measurements a few days in advance, but this requires an 
extra visit. Also a DAS28 based on C-Reactive Protein (C RP) can be calculated, but t he 
gain in time is only limited compared to using the ESR measured by Starrsed in 30 rnin 
mode. Furthermore Castrej6n et al showed that DAS28-ESR and DAS28-CRP are not fully 
equivalent. 1° Finally other disease activity scores not using ESR as one of their components 
can be used, like for example the CDAI, but since a considerable difference between t he 
various scores was revealed further research seems warranted before using these indices 
in cl inical practicen -12 Feasible options at the moment are thus limited to the application 
of rapid ESR analysers or the use of the ESR of the previous visit. 
Several automated ESR analysers are available nowadays, including the Alifax Roller 
Test-1TH with an analyses time of 3 minutesn-15 Automated rapid ESR analysers have 
shown to have good agreement with the Westergren ESR in terms of intraclass correlat ion 
coefficient> 0.80. 13-15 However, two aspects remain poorly addressed. Firstly, limits 
of agreement (LoA) can be large even with adequate intraclass correlation coefficient 
(ICC). 15 Secondly, as the contribution of the ESR on the DAS28 is a result of a natural 
log transformation, data on agreement between various methods on the basis of non-
transformed ESR scores are not adequate to study the impact on DAS28. Therefore, 
the influence of different ESR measurements on agreement and percentage of patients 
misclassified using the DAS28 is the most important variable to know before using these 
analysers, since this ultimately affects treatment decisions. 
We therefore set out to determine the best alternative for determinat ion of ESR to be 
used for DAS28 assessment in daily cli nical practice, with emphasis on the proportion of 




Study design and analysers 
The study consists of three sub-studies. In the first two studies the ESR and ln(ESR) 
were measured in a cross-sectional study design comparing ESR measured according to 
Westergren with ESR measured after 30 minutes and extrapolated and with a rapid ESR 
analyser, namely the Alifax Roller Test-1 TH. After this, a third longitudinal study was done 
to determine the agreement on the level of DAS28 classification between the Alifax Roller 
Test-1TH and ESR according to Westergren. 
The Alifax Roller Test-1TH measures the sedimentation and aggregation capacity of 
erythrocytes via optical density. During 20 seconds the density is measured a 1 000 times, which 
then allows an approximation of the ESR. The Alifax Rol ler Test-1TH requires less than three 
minutes to assess the ESR (Aiifax S.p.A., Polverara, Italy). ESR according to Westergren was 
measured by Starrsed, which is an automated Westergren method (Mechatronics B.V., Hoorn, 
the Netherlands). This analyser also has an option to extrapolate 30 minute sedimentation 
values to 60 minute Westergren values in a 30 minute mode (30 minutes calculation method). 
Study 1: Starrsed in 30 minutes compared to Westergren by Starrsed in a cross-sectional 
study design 
The ESR was measured in a sample of patients with rheumatologic diseases (RA, Psoriatic 
arthritis (PsA) and spondylarthropathies (SpA)) using the WestE~rgren method via Starrsed 
(ESRwEsr60) and compared to the Starrsed 30 minute mode (ESRwEmo). Mean d ifference 
with 95% Cl, Bland and Altman analyses and ICC were calculated before and after log 
transformation. In Bland and Altman analyses the 95% limits of agreement, estimated by 
mean difference ± 1.96 standard deviation of the differences, provide an interval within 
which 95% of differences between measurements by the two methods are expected to lie.16 
Study 11 : Alifax Roller Test-1TH compared to Westergren by Starrsed in a cross-secti onal 
study design 
In a set of patients with rheumatologic diseases, the ESR was measured by the Alifax Rol ler 
Test-1TH and compared to the 60 minute Westergren method measured by Starrsed. The 
same statistical analyses were done as in sub-study I. 
Study Ill: Alifax Roller Test-1TH co mpared to Westergren by Starrsed in longitudinal 
study design 
The ESR was measured longitudinally in patients with RA who were treated with infl iximab 
using the Alifax Roller Test-1TH and compared to the Starrsed according to the 60 minute 
Westergren method. A DAS28 was measured on several consecutive visits with time interval 
of 4-12 weeks when patients received infl iximab. Disease act ivity was classified - using 
validated cut-off points- as remission when the DAS28 was less than 2.6, as low when 
between 2.6 and 3.2, moderate between 3.2 and 5.1 and high when the DAS28 exceeded 
5.1 H The different ESR measurements were used to calculate the DAS28 and afterwards 
the mean difference in DAS28, LoA, ICC, unweighed kappa (DAS28 classification in a 4 by 
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4 table) and percentage of misclassification were calculated. Finally the same calcu lations 
were done comparing DAS28 using the Westergren ESR measured on the last vis it to the 
DAS28 using current Westergren ESR. 
lt was also investigated what the agreement was in classification of DAS28 change of more 
than 1.2 between two consecutive visits. Hereto, patients were classified as improved> 1 .2, not 
changed, and worsened> 1.2 using the two ESR measurement methods (Aiifax Rol ler Test-1 TH 
and Westergren 60 minutes) and a 3x3 table was made and kappa analyses were done. 
RESULTS 
Study 1: Westergren by Starrsed in 30 minutes compared to Westergren by Starrsed in a 
cross-sectional study design 
In 421 patients with various inflammatory (RA, AS, SpA) rheumatologic diseases ESR was 
measured with Starrsed in 60 and 30 minutes. There was good agreement in ESR values 
measured after 60 minutes and the extrapolated value after 30 minutes, shown by a mE?an 
difference in ESR of only 0.14 (95% Cl -0.3 1 - 0. 59). LoA were -9.4 and 9. 7. Further, the 
ICC was 0.97 (95% Cl 0.96 - 0 .98). After 0.7*1og t ransformation the mean difference 
was even less, -0.01 (95% Cl -0.03- 0.02) and the LoA were -0.47 and 0.45. The ICC was 
0.93 (95% Cl 0.92- 0.94) (table 1). 
Study 11: Alifax Roller Test-1TH compared to Westergren by Starrsed in a cross-sectional 
study design 
In 12 5 patients with various inflammatory rheumatologic diseases the mean difference in 
ESR between Westergren and Alifax Roller Test-1TH was -4.4 (95% Cl -7.8 - -1.0). The 
ICC between Alifax Roller Test-1TH and Westergren was 0.67 (95% Cl 0.56 - 0.76). The 
LoA between the different methods were -42.6 to 33.8. After 0.7*1og transformation the 
mean difference between Westergren and Alifax Roller Test-1TH was -0 .01 (95% Cl -0 .12 
- 0.1 0). The ICC between Westergren and Alifax Roller Test-1TH was 0 . 74 (0.65 - 0 .81 ). 
The LoA were - 1.27 to 1.25 after log transformation (table 1 ). 
Study Ill: Alifax Roller Test-1TH compared to Westergren by Starrsed in longitudinal 
study design 
One-hundred-and-twenty-five patients with RA treated w ith infliximab were included. The 
group consisted of 86 women and 39 men, and their average age was 59 years (standard 
deviation (SD) 12). DAS28 at inclusion was 3.6 (SD 1.1) and ESR values ranged from 2' to 
120 with both analysers. The mean difference in ESR was 15.1 and LoA were betwE?en 
-18.2 and 48.4 (see figure 1 ). The mean difference in DAS28 between the two methods 
was 0.29 (SD 0.28), with LoA between -0.27 and 0.85 (see figure 2). The ICC in DAS28 was 
0.93 (95% Cl 0.71-0.97). The kappa was 0.61 and of all patients 26% were misclassif ied, 
with a slight tendency towards overestimation of the disease activity (table 2). 
The DAS28 based on the Westergren ESR of the preceding visit had a mean difference 




Table 1. Mean difference, LoA and ICC of ESR measured by Starrsed in 30 minutes and A lifax Roller Test- 1 compared to the ESR measured 
by the Westergren method (sub study I and 11). 
Mean difference (95% Cl) LoA ICC 
Untransformed 0.7 * Ln Untransformed 0.7* ln Untransformed 0.7* Ln 
ESRwEsr60 vs ESRwEmo (n= 421) 
0.14 -0.01 
-9.4; 9.7 -0.47 ; 0.45 0.97 0.93 (-0.3 1 - 0.60) (-0.03-0.01) (0.96-0.98) (0 .92-0.94) 
ESRwEsr60 vs Alifax (n= 125) 
-4.4 -0.01 
-43; 34 -0 .98 ; 0 .87 0.67 0.74 (-7 .8 - -1.0) (-0.09-0.07) (0.56-0 .76) (0 .65-0.81) 
LoA= limits of agreement; ICC= lntraclass Correlation Coefficient; ESR= Erythrocyte sedimentation rate; ESRwEST6o= ESR measured by Westergren method in 60 
minutes; ESRwEsno= ESR measured by Westergren method in 30 minutes and extrapolated to 60 minutes; 95% Cl= 95% confidence interval 
Table 2. Mean difference, LoA, ICC, kappa and DAS28 misclassification in DAS28 with ESR measured by Al ifax Roller Test-1 and with the 
previous ESR compared to the ESR measured by the Westergren method . 
DAS28 Ahfax VS DAS28WEST60 
DAS28 ESRpreviousvisit VS DAS28WEST60 
Mean difference (SD) 





ICC (95 % Cl) 
0.93 (0.7 1-0.97) 







LoA= limits of agreement; ICC= lntraclass Correlation Coefficient; DAS28= Disease Activity Score 28; ESR= Erythrocyte sed imentation rate; ESRwm60= ESR 
measured by Westergren method in 60 minutes; ESRwEsno= ESR measured by Westergren method in 30 minutes and extrapolated to 60 minutes; 95% Cl= 
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Figure 2. Bland and Altman analysis of DAS28 calculated with ESR measured by Starrsed and 
Alifax Roller Test-1TH . 
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kappa and percentage of misclassification were 0.96, 0.68 and 22% respectively, and 
results were comparable to values found using the Al ifax Roller Test-1 TH (table 2). 
When the patients were categorized according to change in DAS28 between two 
consecutive visits, change was misclassified in 9.6% of the patients with a kappa of 0.63 . 
The re latively low percentage of misclassif ication compared to the modest kappa was 
caused by a low incidence of DAS28 change: 81% of the patients did not have a change 
in DAS28 exceeding -1 .2 or 1.2 according to both ESR measurement methods (table 3). 
Table 3. 3x3 table of change in DAS28 where ESR is measured by Westergren and then 
compared to change in DAS28 when ESR is measured by Alifax Roller Test-1 TH. 
Alifax Roller Test-1TH 
DAS28 change < 1.2 -1 .2 to 1.2 > 1.2 Total 
< -1.2 5 2 0 7 
-1 .2 to 1.2 2 101 2 105 
Westergren 
> 1.2 0 6 7 13 
Total 7 109 9 125 
DAS28= Disease Activity Score 28; ESR= Erythrocyte sed imentation rate 
DISCUSSION 
The ESR measured by analysers like Alifax Roller Test-1 TH compared to Westergren indeed 
demonstrated an acceptable intra-class correlation coefficient.B·15 Limits of agreement, 
however, were very large and a considerable percentage of patients were misclassified 
in DAS28 disease activity level, thus not even outperforming the use of the ESR of the 
previous visit. To see if the initial misclassification of the ESR measured by Alif ax Ro ller 
Test-1TH could be eliminat ed two correction algorithms were used (data not shown). First 
the ESR was corrected for the ratio between ESR measured on the preceding visit by Alifax 
Roller Test-1TH and Westergren. The second correction included the use of individual 
regression analyses to correct the Alifax Rol ler Test-1TH ESR for the individual preceding 
measurements of two previous visits. Our data did not support the use of these correction 
algorithms since the proportion of misclassification did not improve. Furthermore sign if icant 
change in DAS28 was also misclassified in nearly 10% of the patients. Misclassif ication in 
change is lower than misclassification in absolute disease activity, but this overestimates 
the agreement since the proportion of patients with change in DAS28 exceeding 1 .2 was 
low (81% of patients had no change in DAS28 of more than or less than 1.2 between the 
two visits). This is ill ustrated by a moderate kappa of 0.6 despite the low percentage of 
misclassification . The Starrsed 30 minute ESR however appears to be a good alternative to 
the 60 minute measurement with small limits of agreement and a very good ICC. 
Internal va lidity of our study seems adequate. The groups were adequate in size, as 
witnessed by the small confidence intervals on all measures . The third sub-study was 
performed in a longitudinal cohort of 125 RA patients, representative for RA patients in 
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daily clinical practice. Ideally all ESR measurement techniques could have been used in the 
last experiment, however this was not possible due to practical reasons, such as conversion 
and calibrating issues when using simultaneously the St arrsed in 30 and 60 minute mode. 
However, the use of several different ESR values (Westergren 60 minute and 30 minute 
mode, Alifax and previous visit Westergren) and different analyses techniques (ICC, LoA, 
DAS28 misclassification, DAS28 change misclassification) remain strong points of our study. 
In addition to showing that the Alifax is not superior for daily cl inical use to determ ine 
the DAS28 than use of the ESR of the previous visit. our data underscore the notion that 
to investigate the influence of the method used for ESR determination on the DAS28, it is 
not enough to only use correlation and kappa statistics . The percentage of misclassification 
can be substantial even when ICC and kappa seem adequate, as demonstrated by the 
LoA. These differences between the methods used to determine the test characteristics of 
a test strongly support the need to investigate a test in the same way as it is used in daily 
practice. Another point of interest in the assessment of a new ESR measurement method 
is that any alternative should at least outperform the misclassification based on the ESR 
of the previous visit. Our results showed no difference between the performance of the 
Alifax Roller Test-1 TH and the use of the ESR of the previous visit. 
Some points of discussion remain. For example, the percentage of misclassification would 
be smaller if the DAS is calculated instead of the DAS28, since the relative contribution of 
the ESR is smaller in t his calculation . However, the DAS is more extensive and therefore more 
time consuming. A second argument that can be made in favour for the use of rapid ESR 
analysers could be that it is only relevant t o classify patients in low and non-low (moderate 
and high) disease activity. Although this also would reduce misdassification (from 26% to 
1 5% in our study), this would hamper the measurement of remission, which cou ld be the 
future goal of RA therapy. Thirdly, all va lidation work on the DAS(28) has originally been 
done using the ESR according t o the Westergren, either by hand or automated using the 
Starrsed (unpublished data). This supports our choice for the Starrsed as gold standard, but 
DAS28 validation can of course be repeated using other methods as well. Finally, we've 
focused on the influence of different ESR measurement in DAS28 misclassification, but 
random or systematic errors in measuring the other components of the DAS28 can also 
cause misclassification and the magnitude of these errors in clinical practice are thus f ar not 
fully known . Also, other rapid ESR measurement methods might become avai lable in the 
future, and their influence on DAS28 misclassification may be rnore acceptable . 
Only one other study concern ing this subject has been published. Levitus et al also 
investigated the influence of ESR measurement by Al ifax Roller Test-1 TH on disease activity 
classification in patients with rheumatoid arthritis. 17 Comparable - though somewhat 
smaller - percentages of misclassif ication were found (11% vs '15%) when disease activity 
was classified in two levels. Their study, however, did not- amongst other things- include 
the use of other ESR methods like Starrsed 30 minute mode and previous ESR, did not use 
longitudinal data and also did not assess misclassification of change in DAS28.17 
In conclusion, it is important to realize according to which method ESR is calculated in 
clinical practice since it substantially affects the validity of the DAS28, the use of w hich is 
advocated by guidelines.18-20 Alifax Roller Test- lTH - though used in many laboratories -
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To describe rheumatoid arthritis (RA) worsening that leads to change or reinitiating 
of treatment, several Disease activity Score 28 (DAS28) based flare criteria have b!?en 
described, but none have been validated. 
Methods 
Six previously published DAS28-based flare criteria [ 1) increase in DAS28> 1 2, or > 0.6 
if DAS28> 5.1; 2) increase in DAS28> 1.2, or > 0.6 if DAS282 3.2; 3) increase> 0.6 or 
DAS28> 3.2; 4) increase in DAS28> 1.2, 5) DAS28> 3.2; 6) DAS28> 2.6] were tested 
against five hypotheses concerning criterion and construct validity: 1 +2) Sensitivity and 
specificity> 70% compared to patient 's/physician's judgment; 3) difference in proportion 
with DMARD/corticosteroid initiation/increase> 0.2; 4) mean difference in C RP> 1 Omg/1, 
and 5) no statistical difference in Short Form-36 Mental Health subscale change. Three 
different RA patient databases in which flare might occur were used. Sensitivity/specific: ity, 
Chi-square and two-sample student's t-test analyses were done. 
Results 
The analyses included 51, 147 and 744 RA patients, respectively, from the 3 data bases. 
Criterion 2 (increase in DAS28> 1.2, or > 0.6 if DAS282 3.2) fulfilled most hypotheses: 
4 out of 5. Sensitivity and specificity varied between 63-78% and 84-92% respectively. 
Construct validity was demonstrated with 23% more treatment change, higher mean CRP 
(11.4mg/l) and change in depression scale of only -5 . Criteria 3, 5 and 6 tended to be 
more sensitive, criteria 1, 2 and 4 more specific. 
Conclusion 
An increase in DAS28> 1.2, or > 0.6 if DAS282 3.2 appears most discriminating and 
valid by our predefined validation criteria. Considering the other criteria, sensitivity and 
specificity shown in these analyses may facilitate use in different settings. 
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INTRODUCTION 
In rheumatoid arthritis (RA) assessment, the emphasis has been placed on determining 
response to therapy and measurement of states of adequate disease activity contro l, 
rather than on worsening of disease activity (flare). Indeed . several validated criteria 
for improvement are being used in randomised controlled trials (RCTs) and longitudinal 
observational studies (LOS), among them criteria based on relative improvement (American 
Col lege of Rheumatology (ACR) response) and criteria based on relative and absolute 
improvement from baseline (European League Against Rheumatism (EULAR) response). 
Next to improvement criteria, absolute targets for low disease act ivity and remission 
have also been validated (Disease Activity Score (DAS), DAS28, ACR remission criteria)H 
However, increasing numbers of RCTs and LOS are evaluatin~1 treatment strategies that 
include optimisation, tapering and withdrawal of biologic and traditional DMARDs, and 
thus, there is a need for val id measures to determine RA flare or worseningu .s 
Flare criteria in RA are essential for some type of studies and important for other 
type of studies described below. Firstly, flare criteria are necessary to evaluate duration 
of response, with subsequent need for and timing of retreatment after 'fire-and-forget' 
types of treatment like rituximab 9 In addition, when evaluat ing two different treatment 
regimens the number of flare events (including duration and intensity) cou ld be a 
valuable secondary outcome measure in RCTs, besides response at a cert ain t ime point. 
Most importantly, validated flare criteria are indispensable for evaluating the effects of 
dose down-titration or withdrawal of medication in patients w ith low disease activity or 
remission. 10 This is a topic of growing importance as more widespread use of biolog ies 
is limited by costs, and as there is continuing uncertainty about possible long-term side 
effects. 11 In addition to the use of such criteria in RCTs and LOS, they could also provide 
evidence and guidance for treatment optimisation and changes in clinical practice. 
Several unvalidated RA f lare criteria have been used in clinical studies or have been 
proposed in the literature; these criteria vary considerably, from an increase in arthritis 
activity determined by physician's decision to change treatment as described by Bingham 
et al, or any disease exacerbation either transient or persistenlt as described by Berthelot 
et al, or worsening of components of the ACR response criteria or worsening based on 
the inverse of EULAR response criteria. 1•12 Focusing on the Disease Activity Score for a 28-
joint count (DAS28)-based f lare criteria, again several variations have been described, but 
unti l now no validation of these criteria has been publishedn-zo Therefore, we set out to 
examine the performance on criterion and construct validity of DAS28-based flare criteria 
that have been used in published studies. 
METHODS 
To investigate criterion and construct validity of the DAS28-basecl flare criteria, we examined 
four candidate databases to determine usefulness according to presence of at least one non-
DAS28 indicator of RA worsening data and avai lable DAS28 data. 15.2 1•23 Three databases 
met our criteria. Five hypotheses were formulated using the quality criteria for measurement 
properties by Terwee et alas a guidance24 Each hypothesis was tested in at least one database: 
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Database 1: lnfliximab observational down-titration study of the Sint Maartenskliniek 
Nijmegen (n= 51 patients), where infliximab was de-escalated in RA patients w ith low 
DAS28 unti l disease activity worsened or infliximab was stopped. 21 
Database 2: A longitudinal, observational cohort of RA patients treated with infliximab 
for at least 6 months (n= 14 7 patients). 23 
In both database 1 and 2 data was collected on DAS28 and a transition question about 
disease activity every visit. 
Database 3: The NOR-DMARD database, which is a registry of Norwegian patients with 
rheumatic diseases starting treatment with synthetic or/and biologic DMARDs (patients 
w ith RA n= 3612)22 Further detail on the used databases is provided in table 1. 
The following DAS28-based flare criteria have been used in published studies and were 
therefore included in this validation study: 
1. increase in DAS28> 1.2, or> 0.6 if the current DAS28> 5.113•14 
2. increase in DAS28> 1.2, or> 0.6 if the DAS28~ 3.2 15·21 
3. increase> 0.6 or a DAS28> 3.2 16 
4. increase in DAS28> 1.217 
5. reaching a DAS28> 3.2 18 
6. reaching a DAS28> 2.619·20 
These criteria were identified by means of a literature search using the terms: f lare, worsening, 
RA, DAS28. Additional references were identified from references with in these publications, 
ACR, EULAR meetings and individual investigators. 1 Each flare criterion was tested against 5 
hypotheses (as described below). We postulated that at least 4 out of 5 hypotheses should be 
met to conclude that a flare criterion has sufficient construct and criterion validity24 
Criterion validity 
To investigate criterion validity we set out to compare the DAS28-based flare criteria to a 
concurrent gold standard. Since, unfortunately, no gold standard is available, a transition 
question completed by patient and physician was used as a proxy. The transition question 
asked whether disease activity had worsened, remained unchanged or improved compared 
to the last visit by means of a 7-point Likert scale (data bases 1 +2). 
Two hypotheses were formulated: 
Hypothesis 1: Sensitivity and specificity for the different DAS28-based f lare critE?ria 
exceeds 70% compared to the judgment of the patient, operationalized by the 
transition scales of "worse" or "much worse" . 
Hypothesis 2: Equal to hypothesis 1, only compared to physician's judgement. 
Construct validity: discriminative validity 
The construct of the DAS28 validity for measuring disease activity state in RA has been 
extensively validated, and clinically important improvement has also been validated in 
the development EULAR moderate and good response definitions.4·25 However, cl inical ly 
relevant disease activity worsening has not been validated. Because the proposed f lare 
criteria included several different cut off levels for absolute disease activity and change in 
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disease activity, we chose to also reassess construct va lidity. To investigate discriminative 
validity, we hypothesised that in RA patients changing therapy a significantly higher 
proportion wi ll fulfil the flare criteria, operationalized as follows using database 3: 
Hypothesis 3: A significantly higher proportion of patients fu lf illing the flare critt?ria 
had DMARD initiation/increase or corticosteroid in itiation/increase than patients not 
fulfilling the flare criteria. An acceptable higher proportion was defined as 0.2 or 
more. This analysis included only pat ients with DAS28> 3.2 at entry in the NOR-
DMARD database (start of new DMARD treatment) and who had subsequently 
responded after 3 months of treatment. defined as answering the transition question 
with "improved" or "much improved" compared to baseline. For this purpose, change 
in DMARD treatment was defined as DMARD initiation/increase (other than increased 
dose/reduced interval) or/and any initiation/increase in systemic corticosteroids. 
At 6 months patients with a flare were identified by the number of DAS28-based flare 
criteria fulfi lled and whether or not a treatment change had occurred . According to sample 
size estimation with alpha= 0.05 and an anticipated statistical power of 80% to demonstrate 
a proportion difference of at least 0.2, 62 patients were necessary in each group. Chi-square 
analyses were done to test for homogeneity, and to explore whether there was a potential 
statistically significant difference in patients fulfi lling the flare criteria between the groups 
estimated using the absolute difference in proportions (6= n 1 - n 2 "' p1 - p). 
Construct validity: convergent validity 
To assess whether patients classified as having a flare according to the DAS28-based 
criteria also show change in other variables that would be expected to converge w ith the 
RA flare construct. we chose to use change in (-reactive protein (CRP). 
Hypothesis 4: In patients fulfilling the flare criteria the mean change in C RP I E~ve l 
between present and previous visit is signif icantly and relevantly higher (mt?an 
difference> 10 mg/1) compared with patients not fulfilling the flare criteria. 
This hypothesis was tested in database 3 in which changes in CRP level between 3 and 6 
months were compared between patients meeting flare criteria and those not meeting the 
criteria at 6 months using a two-sample Student t-test. Besides a statistical difference we 
expected the difference in mean change of CRP between the flare visits and the non-f lare 
visits to be at least 10 mg/1 24 
Construct validity: discriminant validity 
To test that the DAS28-based flare criteria are not influenced in a relevant w ay by other 
constructs besides disease activity, we tested the hypothesis that there is no relevant 
association between changes in depression and experiencing a flare or not. 
Hypothesis 5: There is no statistical and relevant difference in change in depression 
state measured with Mental Health subscale of the SF-36 in patients fulfi lli ng the f lare 
criteria and patients not fulfilling the flare criteria. 
In patients in the NOR-DMARD database the SF-36 was completed during follow up. P1s a 
measure of feelings of depression or nervousness the subscales of Mental Health were used. 
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Comparison of mean change in Mental Health subscale score in patients meeting and not 
meeting flare criteria wil l be tested with a two sample t-test. To ensure a sufficient power 
to be able to find a difference that is considered relevant (5 points (standard deviation 
(sd) 23)) at least 74 pat ients per group have to be included, according to a sample size 
calculation with alpha 0.05 and anticipated power of 80%, expecting a sd of 10.82 6 
RESULTS 
Demographic data on patients of the three databases used in the validation ana lyses are 
described in table 2. Included patients were predominantly female and rheumatoid factor 
(68-82%) and anti-citrullinated protein antibody (AC PA) positive (69-73%). Cohort 1 and 
2 consisted of RA patients with longer disease duration and had been treated with more 
DMARDs as expected. In cohort 3 patients had shorter disease duration and had been 
treated with fewer DMARDs and included 744 patients fulfilling the inclusion criteria 
for the analyses as well as having available 6-month follow-up data. In al l, 93 of these 
patients had a change in DMARD/systemic corticosteroid treatment, as defined above 
for hypothesis 3. Since inclusion in cohort 3 coincided with starting or chang ing DMARD 
treatment, a higher mean DAS28 at basel ine was observed, but after three months. of 
treatment the mean DAS28 was comparable with the other databases (table 2). 
In tables 3 and 4 the absolute and relative resu lts for the 6 different DAS28-based f lare 
criteria in fulfilling the 5 hypotheses are presented. None of the investigated DAS28-based 
f lare criteria met all hypotheses; criterion 2, however, fulfilled the predefined target of at 
least 4 out of 5 hypotheses. When considering criterion validity for criterion 2, sensitivity 
Table 2. Baseline characteristics for analyses- mean (standard deviation) unless otherwise 
noted. 
Database 1 2 3 
Number of patients 51 147 744 
Age, years 59 (11.2) 58 (12) 56 (13.5) 
Female, n (%) 29 (57) 101 (69) 539 (72) 
Disease duration in years 14 (7 .5) 11 (7) 6.4 (9 .5) 
RF positive, n (%) 42 (82) 117 (81) 496 (68) 
Anti CCP positive, n (%) 37 (73) 95 (69) 146 (70) 
DAS28 at inclusion 2.5 (0.7) 3.5 (1 .3) 5.2 (1 .1) 
3.4 (1.2)* 
Previous DMARDs, median [p25-p75] 3 [2-3] 3 [2 -3] 0 [0-2] 
*Data at 3 months after inclusion in NOR-DMARD. RF= Rheumatoid Factor; ACPA= anti-Cyclic Citrul-
linated Protein; 
DAS28= Disease Activity Score of 28 joints; DMARD= Disease Modifying Anti-Rheumatic Drugs; 
p25-p75= interquartile ranges 
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Table 3. Absolute result s of the DAS28 based flare criteria on fulfi lling the 5 hypotheses regarding construct and criterion validity. 
Criterion validity: Construct validity: 
database 1 and 2 database 3 
Flare criteria Hypothesis 1 Hypothesis 2 Hypothesis 3 Hypothesis 4 Hypothesis 5 
Sens/spec Sens/spec Higher proportion No change 
patient> 70 % physician> 70% of DMARD/ Larger change in depression 
In patients classified compared to compared to corticosteroid in CRP (:<;; 5 points 
as a having a flare transition scale transition scale change (> 0.2) (> 10 mgll) in MH scale) 
Sens* Spec* Sens* Spec* Proportion CRP difference MH difference 
% % % % difference** mg/1 (SE}** * (SE}*** 
1) 6DAS28> 1.2 or> 0.6 if DAS28> 5. 1 46/56 95/92 53/78 95/92 0.28 13.1 (2 .2) -6 .1 (1.4) 
2) 6DAS28> 1.2 or> 0.6 if DAS28> 3.2 69/63 92/84 73/78 92/86 0.23 11.4 (1 .7) -5 .0 (1 .2) 
3) 6 DAS28> 0.6 or DAS28> 3.2 98/94 70/61 100/89 67/60 0. 16 3.7 (1.2) -2 .8 (1.0) 
4) 6DAS28> 1 .2 46/56 96/93 51/78 95/92 0.27 13.0 (2 .3) -6 .6 (1 .4) 
5) reaching DAS28> 3.2 91/88 78/67 91/89 76/68 0.18 3.1 (1 .2) -2 .6 (1 .0) 
6) reaching DAS28> 2.6 98/94 55/46 100/89 53/47 0.13 2.4 (1.0) -3 .2 (1 .1) 
Sens= sensitivity; Spec= specificity; DMARD= Disease Modifying Anti-Rheumatic Drugs; CRP= (-Reactive Protein; MH= Mental health subscale of the SF-36; 
DAS28= Disease Activity Score of 28 joints 
*Results from database1 I database2 are represented on sensitivity and specificity. 
**Al l proportion differences were tested with Chi square analyses and statistically significant with p< 0.0001. 







Table 4. Relative results of the 6 different DAS28 based flare criteria on fulfilling the 5 hypotheses. 
Criterion validity: database 1 and 2 
Flare criteria Hypothesis 1 Hypothesis 2 
--------------------------------~---------
In patients classified 
as a having a flare 
1) L'>DAS28> 1.2 or> 0.6 if DAS28> 5.1 
2) L'>DAS28> 1.2 or> 0.6 if DAS28> 3 .2 
3) L'>DAS28> 0.6 or a DAS28> 3.2 
4) L'>DAS28> 1 .2 
5) reaching DAS28> 3.2 
6) reaching DAS28> 2.6 
Sensl spec patient 
> 70% compared 








> 70 % compared 








Construct validity: database 3 
Hypothesis 3 Hypothesis 4 Hypothesis 5 
Higher proportion 
of DMARDI Larger 
corticosteroid change No change 
change in CRP in depression 
Fulfilled Fulfilled Fulfilled 
+ I - +I - + I -
+ + 
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and specificity varied between 63-78% and 84-92% respectively. Discriminative validity 
was demonstrated with a higher proportion of change in RA treatment (difference in 
proportion of 0.23). Convergent val idity was shown with a higher mean CRP of 11.4 mg/1 
(SD 1. 7) in patients defined as having a flare. Last. there was no change in depression scale 
(-5 (SD 1.2)) supporting discriminant validity. 
When considering criterion validity, most flare criteria seem to be either very sensitive 
or very specific. The criteria only using an absolute DAS28 cut-off to define a flare are 
very sensitive, but they lack specificity (criterion 5 and 6). If only amount of worsening in 
DAS28 is used in the criterion the opposite is observed, with high specificity and lower 
sensitivity (criterion 4). The criteria using a combination of a threshold and a change over 
time are more sensitive or more specific depending on whether a threshold of 3.2 or 5.1 is 
used and whether the change in DAS28 is more than one or two times the measurement 
error (0.6 or 1.2) (criterion 1, 2 and 3). In addition there is a rather high correlation 
between the transition questions of patients and physicians used in hypotheses 1 and 2 
(cohort 1: r= 0.76, p< 0.0001; cohort 2: r= 0.82, p< 0.0001), resulting in simi lar sensit ivity 
and specificity results between these hypotheses. 
Flare criteria with DAS28 change of more than two times the measurement error fulfil 
hypotheses 3 and 4 (discriminative and convergent validity), in contrast to criteria not 
including a change measure or including a change measure of > 0.6 (table 4). Criteria 
including cut-offs for DAS28 state, with or without a small DAS28 change, fu lf illed 
hypothesis 5, which assesses discriminant validity. Discriminant validity of flare criterion 2 
is just at the predefined acceptable limit. 
DISCUSSION 
To our knowledge, this is the first study to examine the performance of the DAS28-based 
flare criteria that have been used in published studies in terms of criterion and construct 
validity. Performance varied considerably, with the only DAS28-based flare criterion that 
met the predefined validation threshold being an increase in DAS28> 1.2, or > 0.6 if the 
DAS28~ 3.2. In addition, flare criteria including a more stringent DAS28 change measure 
have higher discriminative and convergent validity, suggesting a better signal to noise 
ratio. In contrast, the criteria with cut-offs for DAS28 state with or without a small DAS28 
change measure performed better on testing of discriminant validity. Overall, construct 
validity revealed a comparable trend to criterion valid ity, where the criteria using a DAS28 
change measure of> 1 .2 are more specific and if a cut-off with or without a small DAS28 
change of> 0.6 is used the criteria have higher sensitivity. 
Our study has several strengths. Firstly, a stringent study protocol was developed and 
followed, closely adhering to validation techniques described by Terwee et al and using 
pre-specified endpoints z4 In addition, four different databases were assessed for usE~ in 
our analyses . After selection based on availability of necessary data and appropriateness 
of data collection for our predefined analyses, three databases were used to test the 
DAS28-based flare criteria. In these databases RA patients with short and long disease 
duration were included which to our opinion increases generalisability of our results to 
determine clinically relevant worsening of RA disease activity. 
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Due to the elaborated insight into the performance of the different flare criteria, an evidence-
based selection can now be made depending on the goals for the use of the flare criterion. For 
example in an RA cohort with patients in remission there might be a need for a more sensitive 
criterion than for example RA patients treated with rituximab who have not reached remission 
yet but experience a flare after a good initial response. However, since none of the flare criteria 
completely fulfilled all our predefined hypotheses further research and development of a flare 
measurement is warranted, with emphasis on the potential role of patient reported outcomes, 
especial ly since disease flare may not coincide with assessment visit. 
Some limitations of our study and of validation studies in general should be ment ioned. 
First and foremost, no gold standard for RA flare is available. In assessing criterion val idity, 
transit ion questions completed by patients and physicians were used, which might be 
considered as a reasonable proxy for a gold standard. We have considered using radiographic 
damage to assess criterion validity gold standard. However, this reflects a late consequence 
of f laring of disease activity, thus qualifying more for construct va lidity. Also, rad iographic 
damage is becoming more infrequent due to limited sensitivity of the measure and better 
disease control in most RA cohorts. Hypothetically loss of function could also be used as 
a gold standard for flare. In the NOR-DMARD database the Modified Health Assessment 
Questionnaire (MHAQ) was collected, as a validated quest ionnaire for functionP In 
this database treatment change and patient reported worsening correlate w ith MHAQ 
worsening 28 However no publications are at hand on a threshold for MHAQ change to 
be defined as having a flare. Finally, intensity of morning stiffness was also correlated to 
patient reported worsening in NOR-DMARD, but again there is up till now no evidence that 
this parameter is a gold standard for flare. So in conclusion, patient's judgement on disease 
activity deteriorat ion seemed the most feasible and reasonable option as a 'gold st andard'. 
Another shortcoming could be the lack of involving a definition for persistence of a 
flare in terms of duration of DAS28 worsening. However, none of the databases available 
included data to enable this analysis. If the OMERACT definition of flare in RA is taken 
into account, a f lare needs to include duration of disease worsening. We analysed all flares 
based on single visits. If duration is also included, with for example a second measurement 
after 1-2 weeks, the reported f lare criteria will probably increase in specificity, but lose 
sensitivity. This requires further study. 
In addit ion, the absolut e results f or hypothesis 3 are perhaps somewhat disappointing . 
One might have expected an even higher proportion of patients fulfilling a flare criterion 
to have had a change in treatment. As anticipated on, doctors and patients can be 
reluctant t o change medication for many reasons; for example, waiting for improvement 
because medication has just started, or fearing side eff ects of alternative medications. 
Also, from start of patient inclusion in the NOR-DMARD database several years ago t o now 
attitudes have changed with regard to therapeutic strategies. Nowadays a tight control-
based approach is much more common than previously, which will have influenced the 
proportion of treatment changes in th is database. Finally, more hypotheses could have 
been generated to test validity resulting in more accuracy and also other flare criteria 
(DAS/CDAI/SDAI/ACR based for example) could have been included. 
In conclusion, based on these results, an increase in DAS28> 1.2, or> 0.6 if the DAS28~ 
3.2 seems an adequate flare criterion when considering criterion and construct validity. 
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Also, it appears that DAS28 criteria for disease worsening can be selected according to 
study requirements for sensitivity and specificity to guide treatment strategies. In t he case 
of studies evaluating dose-titration and withdrawal, the duration of worsening that should 
trigger resumption of medication at t he previous level is unclear, and warrants further study. 
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Down-titration, or discontinuing infliximab, has proven to be feasible in RA patients. 
Therefore, our local treatment protocol includes tapering infliximab dose. This observational 
study describes the prevalence of successful down-titration in daily cl inical practice and its 
effect on costs and quality of life (QoL). 
Methods 
lnfliximab was down-titrated with 25% of the original dose (3mg/kg) every 8-12 weeks 
without interval change until discontinuation or f lare in all RA patients with stable low 28-
joint disease activity score (DAS28) and stable treatment for >6 months. During one year 
DAS28, RA medication, outpatient clinic visits, RA related absenteeism and EuroQol.5D 
(European Qol questionnaire, EQ5D) were documented. Prevalence of successful down-
titration and changes in DAS28, quality of life (Qol) and costs were described. 
Res ults 
In 16% (95% confidence interval (Cl)= 6-26) and 45% (95% Cl= 31-59) infl iximab could 
be discontinued or down-titrated respectively. Mean infliximab dose decreased significantly 
from 224mg (95%CI= 212-236mg) at start, to 130mg (95% Cl= 1 05-154mg) after 1 year. 
Median DAS28 increased from 2.5 (p25-75= 2.0-2.9) to 2.8 (2.2-3.6) (p= 0.002). E><tra 
corticosteroids were given in 8% of the visits. Disease modifying anti-rheumatic drugs 
were seldom changed. There was no statistical difference in QoL after down-titration. 
Mean reduction in the costs was 3474 Euro (95% Cl= 2457-4492) per patient. 
Conclusion 
In the majority of patients with stable low DAS28 and stable treatment infliximab can be 
down-titrated or discontinued, which results in a considerable reduction in costs w ithout 
influencing QoL. 
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INTRODUCTION 
The objective of treatment with disease modifying anti-rheumatic drugs (DMARDs) 
or biologies in rheumatoid arthritis (RA) is to determine the optimal dose of the drug 
and thus maximise its effect and minimise dose related side effects and costs. Frequent 
monitoring of disease activity, establishing targets for the desired level of disease activity 
and increasing therapy when the disease is too active, has proved to be more effective 
than routine outpatient care. 1-6 However a disadvantage of a hit-hard-and-h it-ear ly 
strategy is that it may lead to overtreatmenU-10 This is also the case for anti-TNF inhibitors 
like infliximab, which is an effective treatment for RA, however is also associated with high 
cost and increased risk for adverse effects like infection and possibly malignancies.6· 11- 15 As 
a result overtreatment with infliximab is undesirable. 
Reducing overtreatment in RA patients with long-term low disease activity seems 
feasible since RA patients treated with biologies like infliximab, who reach low disease 
activity or remission, can theoretically be divided in at least three subgroups: a subgroup 
of patients with low disease activity or remission caused by an adequate infl iximab dose, 
a subgroup with adequate disease control due to infliximab, but who would also maintain 
disease control with a lower dose and fina lly a subgroup w ith low disease activity unrelated 
to infliximab treatment, who would fare equally well without iL The existence of the latter 
group seems contra- intuitive, however, two possible explanat1ions exist. Firstly the in itial 
apparent "response" may be caused by regression-to-the-mean, as witnessed by response 
percentages in placebo treated patients in anti-TNF randomised control led tria ls. Secondly, 
infliximab was only temporarily necessary to gain control of the disease. 7-10 To find the 
optimal dose down-titration and discontinuation are warranted. 
The feasibility of down-titration or discontinuation of biologic treatment in RA patients 
with low disease activity or remission has been demonstrated by several studies. 16-22 
Therefore, the local treatment protocol in our hospital includes a combination of disease 
activity guided tapering of the infliximab dose, and ultimately discontinuation in RA 
patients with long term stable low disease activity and treatment. Since there is not much 
data available about the combination of both down-titration and discontinuation in RA 
patients, or about the prevalence of successful down-titration in daily clinical practice 
we conducted an observational study. Furthermore, we evaluated the effects of down-
titrating infliximab dose on disease activity, quality of life (Qol} and direct costs. 
METHODS 
All RA patients (fulfilling the American Rheumatology Association crit eria 1987) of the Sint 
Maartenskliniek Nijmegen, The Netherlands, treated with infliximab, who have stable low 
disease activity, defined as a 28 joint disease activity score (DAS28)< 3.2 (in accordance 
with previous infliximab discontinuation studies), and stable anti -rheumatic treatment 
for at least 6 months are treated according to our local down-titration protocol. 21 •23•24 
As stated in this protocol the infliximab dose is tapered with 25% of the origina l dose 
(3mg/kg) every 8-12 weeks without changing the interval unt il discontinuat ion or f lare, 
which is defined as an increase in DAS28<> 1.2 compared to baseline on 2 subsequent 
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visits with at least 2 weeks in between visits. 17 After the threshold of DAS28> 3.2 is 
reached, a more stringent criterion is utilised, namely an increase in DAS28~ 0.6. To 
ensure that disease activity will remain adequately controlled all patients of the down-
titration protocol are examined before every infliximab infusion . In addition, patients are 
encouraged to contact the rheumatologist in-between infusions if to their opinion d isease 
activity has deteriorated, which will resu lt in an outpatient clinic evaluation within 1-3 
days. If a patient flares, infliximab dose will be increased to the last effective dose. If 
despite increasing the dose DAS28 remains 3.2 or more, the dose is further increased up 
to 3mg/kg and if necessary therapy is switched to a different biologic. 
From January to April 2010 all patients who started with infliximab down-titration 
were included in an observational cohort to describe the prevalence of successful down-
titration in daily clinical practice. Each patient was followed for 1 year. Demographic data 
including gender, age, weight, disease duration, rheumatoid factor, anti-CCP, erosive 
disease, previous and concomitant DMARD use, previous biologic treatment. concomitant 
NSAID treatment. duration of infliximab treatment and employment were collected. 
Every visit DAS28, change in RA medication (DMARD, NSAID, corticosteroid), number 
of outpatient clinic visits in-between infusions and RA related work-absenteeism were 
documented. Every 4 months Qol was measured by means of the EuroQoLSD. 25 
At f irst infliximab initiation all patients in our cohort had fa iled at least on 2 DMARDs, 
of which one was methotrexate, and had active RA (DAS28> 3.2). Since DAS28 guided 
dose down-titration was performed as usual care for all RA patients, no extra venous 
puncture was necessary and no demanding questionnaires were administered, this 
observational study did not require approval of an ethical committee accord ing to Dutch 
legislation . Written informed consent was given by all patients. 
Statistics 
Descriptive statistics were used for demographic data. Primary outcome was percentage of 
patients successful ly down-titrated and percentage successfully discontinued after 1 year. Per 
down-titration step a Kaplan-Meier curve is provided demonstrating the probability of not 
requiring a dose-re-escalation. Secondary outcomes were the mean difference in infliximab 
dose at baseline and after 1 year tested for statistically significant differences with a Student's 
t-test, as well as median difference in DAS28 per down-titration group (no down-titration , 
partly down-titrated and stopped) with the Kruskai-Wal lis nonparametric test. Furthermore, 
frequencies of DMARD, NSAID and corticosteroid changes were described, next to difference 
in number of outpatient clinic visits in the year of down-titration compared to the preceding 
year. Possible predictors for down-titration were investigated by means of univariate logistic 
regression. Subsequently, multivariate analysis was performed for three possible predictors 
given the sample size of our cohort. These factors were chosen based on explained variance 
found in univariate analyses and based on literature. 
Differences in Qol and direct costs preceding and succeE?di ng down-titration were 
assessed. The cost analysis consisted of two main components: determination of volumes 
of care related to the down-titration protocol and determination of cost prices for each 
volume of consumption. Volumes of care were multiplied with the cost prices to calculate 
costs. As volumes of care were registered out-patient clinic visits, medication use, and 
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work-related absenteeism. Cost prices for medication were retrieved from the Dutch 
National tariff list provided by the Dutch Board of Health lnsurances [August 201 1]. The 
standard cost prices from the 'Dutch Guideline for Cost Analyses' were used for va luat ion 
of hospital related care and work-related absenteeism (201 0). 26 Since we postulated that 
during down-titration extra outpatient clinic visits or concomitant medication use w ill 
have an effect on costs, the reduction in costs was also analysed per 4 months. The last 4 
months is presumed to approximate the new steady state in costs. To investigate change 
in EQSD per 4 months an ANOVA for repeated measures was carried out. 
RESULTS 
In total 94 RA patients were treated with infliximab of whom 51 met the criteria of the 
local down-titration protocol and were observed during one year (figure1 ). Demographic 
data of these patients is depicted in table 1. Patients were treated with concomitant 
methotrexate, however due to side effects 32% were treated with leflunomide, 
azathioprine or lnfliximab monotherapy. Overall data was collected over 421 visits. 
Protocol violations were observed in 7.1 % of all visits. 
94 patients treated with 
IFX were screened 
39 patients not eligible for down-titration J 
1-------+1 - DAS28>3.2 
- RA treatment stable 
55 patients eligible for 
down-titration 
- 1 hospital admission due to infection 
1-------+l - 1 flared before start 
4 dropped out before down-t itration J 
51 pat ients in 
observational cohort 
- 1 treatment change although DAS28<3.2 
- 1 moved to other city 




Table 1. Baseline characteri stics . 
Number of patients 
Age, years (sd* ) 
Female, n (%) 
Weight, kg (sd) 
Disease duration in years, median [p25-p75] 
RF positive, n (%) 
Anti-CCP positive, n (%) 
Erosive disease, n (%) 
DAS28 at inclusion (sd) 
Duration of infliximab therapy, years (sd) 
Interval duration at start, median [p25-p75] 
lnfl iximab dose at start, mg (sd) 
lnfliximab at start, mg/kg (sd) 
No of previous DMARDs, median [p25-p75] 
Previous MTX, n (%) 
Previous anti-TNF-alpha therapy, n (%) 
Concomitant DMARD use, n (%) 
Concomitant MTX use, n (%) 
Concomitant corticosteroid use, n (%) 
Concomitant NSAID use, n (%) 





















16 (3 1) 
sd= standard deviation; n= number; p25-75= interquartile range from 25 to 75%; RF= Rheuma-
toid Factor; Anti-CCP= Anti-Cyclic Citru llinated Protein; DAS28= Disease Activity Score of 28 joints; 
DMARD= Diseases Modifying Anti-rheumatic Drug; MTX= methot rexate; TNF= Tumour Necrosis 
Factor; NSAID= Non-Steroidal Ant i-Inflammatory Drug 
In 16% (95%confidence interval (C l)= 6-26) of the patients infliximab could be stopped 
and in 45% (95% Cl= 31-59) of the patients the dose could be successfully down-titrated 
after one year. In 39% (95% Cl= 26-53) no down-titrat ion was possible, that is, patiE•nts 
returned to the original dose. The proport ion of patients not requiring a dose-re-escalation 
after each down-titration step due to f lare during 1 year follow up is depicted in Figure2 . 
Considering the patients in whom infliximab could be discontinued we verified that at time 
of infliximab initiation all patients had act ive disease (mean DAS28 was 5.9, sd 1.4) and 
88% was rheumatoid factor and anti-cyclic citrullinated peptide (anti-CC P) posit ive. 
Mean infliximab dose decreased significantly from 224mg (95% Cl= 212-236rng) 
at the start to 130 mg (95% Cl= 1 05-154mg) after one year. Expressed in mg/kg the 
dose decreased from 3.0 mg/kg (sd 0.2) to 1.7 mg/kg (sd 1.1 ). Median DAS28 increased 
statistically significantly from 2.5 (p25-75= 2.0-2.9) to 2.8 (p25-75= 2.2-3.6) after 1 year 
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Figure 2. Kaplan-Meier curve demonstrating the probability of not requiring dose-re-escalation 
after each down-titration step (75%-50%-25%-0%) of the inflixirnab dose. 
in the whole group(p= 0.002). An increase in DAS28 was most noticeable in patients 
in whom infliximab dose couldn't be tapered; however differences between groups 
(discontinued, down-titrated and not down-titrated) were not significant (p= 0.14). Fif ty 
percent of the patients in whom infliximab could not be down-titrated were retreated 
with the original infliximab dose within the first 3 visits. Of note, no infusion reactions to 
infliximab were observed during follow up and no changes in infliximab infusion intervals. 
In this cohort no statically significant clinical factors could be found to predict 
successful down-titration (table 2). Based on explained variance smoking, disease duration 
and DAS28 at baseline were investigated in multivariate anaiY'ses revealing an explained 
variance of 10%, p= 0.08.1n addition, methotrexat e use was analysed in different 
sequences w ith 2 of the abovementioned factors without improving explained variance. 
Extra corticosteroids were given in 8% (95% Cl= 5-1 0) of .all 421 visits, which was in 
one third of all patients. In one patient prednisolon was stopped. In addition, three patients 
received corticosteroid injections because of bursitis (two subacromial and one trochanteric) 
and one patient because of a trigger finger. In 15 visits (3.5%) a DMARD change occurred, 
which was in 10 patients. In 7 patients the DMARD dosage was decreased or the DMARD 
was stopped, in 2 patients the dose was increased and in 1 patient methotrexate changed 
into sulfasalazine due to a pregnancy wish. In three patients a different biologic was started. 
All these patients flared after the first down-titration and reached low disease activity again 
after dose increase, but unfortunately secondary failure to infliximab warranted a change 
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Table 2. Predictive clinical baseline factors for successful down-titration . 
Predictive factor Odds Ratio 95% Cl Pseudo R2 Prob>Ch j2 
RF (negative/positive) 1.3 0.30-5.57 0.0018 0.72 
Anti-CCP (negative/positive) 0.7 0.16-3.18 0.0035 0.64 
Age (years) 1.0 0.95-1.05 0.0000 0.98 
Sex (male/female) 1.1 0.36-3.51 0.0007 0.83 
Smoking (no/yes) 5.3 0.59-46.6 0.0454 0.08 
Disease duration (years) 0.9 0.86-1.01 0.0392 0.10 
DAS28 at start 0.6 0.26-1.21 0.0345 0.12 
Duration of infl iximab therapy (years) 0.9 0.73-1.15 0.008 1 0.46 
Methotrexate use (no/yes) 1.3 0.40-4.38 0.0029 0.65 
DMARD use (no/yes) 1.0 0.25-4.28 0.0000 0.95 
Patient's belief on successful down- 2.4 0.71-7.76 0.0292 0.16 titration (no/yes) 
Cl= confidence interval; Pseudo R2= explained variance; anti-CCP= anti-Cyclic Citrullinated Protein; DA$28= 
Disease Activity Score of 28 joints; MTX= methotrexate; DMARD= Diseases Modifying Anti-rheumatic Drug 
in therapy (2 are treated with rituximab and 1 with etanercept). In 42 visits (1 0%) NSAIDs 
were changed, with NSAID initiation in 36 visits. RA related work absenteeism was reported 
by only one patient for two days. Patients did not visit the outpatient clinic more frequently 
during down-tit ration than in the year before infliximab down-t itration (p= 0.16). 
There was no statistically significant difference in Qol after down-titration. The mean 
difference in EQ5D was -0.031 (95% Cl= -0.067- 0.005). If the EQ5D scores were analysed 
per down-titration group no statistically significant difference was found (p= 0.1 52). The 
mean reduction in costs over the whole year was 3474 Euro (95% Cl= 2457-4492) per 
patient. A gradual decline in costs per 4 months was observed (figure 3). If costs in the 
last four months are compared with costs prior to down-titration, the reduction would be 
5689 Euro per patient per year, extrapolated to subsequent years. There is no statistical 
difference in EQ5D between the 4 time points (p= 0.19). 
DISCUSSION 
Our study demonstrated that down-titration or discontinuation of infl iximab is possible in 
the majority of RA patients with stable low disease activity and stable treatment without a 
relevant change in DAS28 and QoL during a one year follow up. Throughout this year the 
direct costs were substantially reduced compared to the year before by more than 3000 
Euros, and this relates to 5689 Euros per patient for the following years if we assume that 
the direct costs of the last 4 months can be extrapolated. In .addition, most flares seem 
to occur within the first 10 to 12 weeks after each dose down-titration step and most 
patients who cannot discontinue already flared after the dose decreased to 75 or 50% . 
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Time (months) 
Figure 3. Mean direct costs in Euro per 4 months. Start of down-titration was at t=O. 
However, it can be assumed that down-titration has some undesirable effects. First 
of all, disease activity can increase. In our cohort a small median increase in DAS28 of 
0.3 was observed, with a tendency towards a larger increasE~ in DAS28 for patients in 
whom down-titration failed. This was however, not significant and might also partia lly 
be explained by regression-to-the-mean effects, because all patients had a DAS28<3.2 
at study start. Secondly, an increase in the use of other RA medication besides infl iximab 
can occur. We mainly observed a small increase in cort icosteroid and NSAID use. DMARD 
dose-increases or changes were relatively uncommon. Thirdly, down-titration might bring 
about an increase in radiographic damage as a result of flares 27 Besides radiograph ic 
follow up as incorporated in daily medical care, no structural data was collected, therefore 
no conclusions can be drawn. Additionally, since anti-TNF-alpha treatment is associated 
with a reduced incidence of cardiovascular events discontinuin9 therapy might abolish this 
effect.28•29 Then again, whether anti-TNF-alpha therapy itself or minimising the systemic 
inflammation is the cause of the reduced incidence remains to be settled beyond doubt. 
Another noteworthy possible down-side of infliximab down-titration might be 
anti -infliximab-antibody formation since previous studies demonstrated an association 
between low serum levels of TNF-alpha-inhibitor and the presence of anti-TNF-alpha-
inhibitor-antibodies leading to secondary failure or infusion related allergic reactions. 30-32 
Additionally, since in our cohort 20% is not simultaneously treated with other 
immunomodulators next to infliximab, the risk of anti-body formation is possibly further 
increased 33 As having ant i-infliximab-antibodies is expected to lead to loss of therapeutic 
effect and occurrence of side effects like allergic infusion reactions it is reassuring that no 
infusion reactions in our cohort have been observed so far. There were 3 patients however 
in whom biologic treatment had to be changed due to secondary fa ilure. Further follow 
up of all patients is required to assess whether in the future more patients will experience 
secondary failure. Of note, an alternative explanation on antibody formation could be 
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that, since the level of anti-infliximab antibodies is the resultant of antibody formation and 
(antigen-bound) antibody clearance, lowering the dose of TNF-alpha-inhibitors (antigen) 
reveals already present antibodies rather than induces new antibody formation. 
If the benefits of down-titration are considered, dose-related side effects of infliximab 
are expected to decline. Although inconsistent and troubled with a precision problem, 
there is evidence for an increased risk of side effects with higher doses of anti-TNF 
blockers suggesting dose-related side effects, implying that a lower dose has beneficial 
effect on the occurrence of side effectsn ·34•36 Furthermore, down-titrating infliximab 
yielded a considerable cost-reduction, while preserving adequate disease activity control 
as demonstrated in our cohort. With ever growing medical health care budgets sensible 
allocation of resources is mandatory, and all costs that can be reduced might, for example, 
be used to improve other health care facilities. 
When looking at internal validity of our study a few limitations are noticeable. First of all, the 
relatively small group of patients might influence precision in secondary outcome measures. 
Then again, confidence intervals around DAS28 and the utilities seem reasonable. Secondly, 
a longer follow-up period is required, to be able to consider secondary ineffectiven1?SS, 
cost reductions in subsequent years and number of side effects. Another drawback of our 
observational study is the lack of a control group in which infliximab dose remains unchanged. 
This hampers accurate conclusions on the effect of down-titration on amongst others DAS28 
difference, number of f lares, other treatment changes, side effects and treatment fa ilure. 
On the other hand for the point-estimate of our primary outcome measure (percentage of 
successful down-titration) and for prediction of successful down-titration no control group 
is necessary, because this would have been zero percent in a hypothetical control group is 
which infliximab is not down-titrated. Additional ly, since all patients in whom infliximab was 
tapered had stable DAS28 and treatment for at least 6 months prior to down-titration we 
can assume that on theoretical ground no flares, treatment changes or DAS28 increases 
should have occurred if the dose had not been reduced. As a result one can assume that a 
control group could only further reinforce our findings compared to the current premise of 
no f lares and medication changes in a usual care context. Additionally, some debate about 
the sensitivity of the measurement of quality of life remains. The EQ5D might not be able 
to detect subtle differences in quality of life due to down-titration. Then again it has been 
validated extensively. Lastly, no validated flare criteria were available at initiation of our down-
titration protocol and the reversed EULAR response criteria were used, which had been used 
in previous studies. 17•22 We modified the criteria to some extent to increase sensitivity. 
To our knowledge this is the first study to combine down-titration and discontinuation 
of biologic treatment. First of all, the other study on down-titration of infliximab tapered 
higher than registered dose.22 In 89% of the patients infliximab could be down titrated from 
5mg/kg to 3 mg/kg. Another study demonstrated that 71% of the patients on adalimumab 
could down-titrate the dose until a flare occurred. In another study etanercept down-titration 
from 2x/week 25mg to l x/week 25mg was investigated, and 73% remained in remissionn·37 
Discontinuation of infliximab in the BeSt and RRR study was successful in 55-56%, which 
is a higher percentage than in our cohort. In the BeSt study however patients had early RA 
opposed to long disease duration. Furthermore they were methotrexate na·lve, therefore it 
can be postulated that methotrexate was responsible for reaching low disease activity. 
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Further research is needed to find predictors of successful down-titration to prevent 
unwarranted dose de-escalation and minimise harm to the patients. In addition, if patients 
who can discontinue biologic treatment are identified no time consuming down-titration 
protocol would be necessary and treatment can be discontinued straight away. Analysis 
in our cohort revealed no significant or relevant predictive factors. Two comments can be 
made. First. due to a small sample size large multivariate analyses were not possible and 
conf idence intervals for univariate analyses were large. Second, other possible candidates for 
prediction should be included in future analysis, such as (anti-)infliximab serum t rough levels, 
ultrasonography or positron emission tomography(PET). Besides prediction, future research 
on down-titration needs the incorporation of an induction phase. consisting of lowering the 
dose and a short follow up to monitor flares, as well as a maintenance phase, to monitor 
long term cost and side effect reductions and secondary failure. Furthermore, down-titration 
protocols for other biologies, including non-TNF-alpha blockers, can be envisioned. 
In conclusion, down-titrating or even discontinuing infliximab is possible in the 
majority of the patients with long standing low disease activity, resulting in a considerable 
cost reduction and possible safety gains. No relevant deterioration of disease activity 
compared to start of down-titration was observed in these patients; however predictors 
for successful down-titration are warranted. 
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To get insight in the prevalence of high, or low/no serum infliximab trough levels in patients 
with low disease activity and if serum trough levels are stable and reliable longitud ina lly 
we conducted a prospective cohort study 
Methods 
In a longitudinal, observational cohort of RA patients treated with infliximab for at 
least 6 months, treatment interval, DAS28, infliximab trough levels and anti- infliximab 
antibodies were assessed. Prevalence of low(< 1 mg/1) and high(> 5mg/l) infliximab serum 
trough levels and anti-infl iximab antibodies was recorded. Relationship of a change in 
anti-infliximab antibodies and treatment interval was described. Reliability of consecuitive 
infliximab serum trough levels and anti-infliximab antibodies in patients with stable DAS28 
and treatment was analysed with Spearman correlation and kappa-analysis. 
Results 
14 7 patients with a mean disease duration of 11 years (sd7) and DAS28 of 3. 5 (sd 1 .3) 
at baseline were followed during 1.5 years. Inter-individual variability in infliximab levels 
in patients with low DAS28 was high (median 1.4mg/L, IQR 3.35), with 31% (9'3% 
Cl= 20-42%) having low(< 1mg/L) and 14% (95% Cl= 5-22) high trough levels(> 5mg/L). 
Interestingly also in RA patients with DAS28~ 3.2, anti-infliximab antibodies were found in 
one-third of the patients, with half of them having antibodies every visit during a median 
of more than one year. Agreement for consecutive measurements of serum t rough levels 
and anti-infliximab antibodies was high in stable patients: r= 0.97 (p= 0.00001) and 
kappa= 1 .0 (SE 0.14) Anti-infliximab antibody appearance was influenced by interval 
increases (relative risk (RR) 5.2, 2.6-10. 7), but patients still showed low infliximab levels. 
Conclusion 
Low (and high) infliximab serum trough levels are prevalent, interestingly also in patie·nts 
with low disease activity. Consecutive measurements of serum trough levels and anti-
infliximab antibodies are reliable in stable patients. These tests could be used to lower or 
stop infliximab in selected patients. 
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INTRODUCTION 
lnfliximab, a chimeric (human-mouse) monoclonal antibody to human tumor necrosis 
factor-a (TNF-a), has proved to be effective in the treatment of rheumatoid arthritis (RA) 
in several pivotal randomised controlled trials.1•2 There is however a difference in response 
between individual RA patients, both in the initiation and in the maintenance phase. 
Differences in response to infliximab in the initiation phase could be partly explained by 
inter-individual differences in pharmacokinetics as reflected in lower infliximab trough 
levels and presence of anti-infliximab antibodies in patients not responding to infliximab3 •7 
In the maintenance phase of treatment with infliximab there are still large inter-
individual differences in disease activity, as witnessed by the relatively high mean and 
large variation in disease activity scores (mean DAS28 in the DREAM registry after one 
year was about 4) and large proportion of patients with high disease activity in biological 
registries (for example about 45% in the NOR-DMARD database had a DAS28> 3.2 after 6 
months) 8 ·9 This can be explained by inadequate initial response, but also by the occurrence 
of secondary loss of response after initial improvement on infliximab. Therefore further 
improvement of treatment regimens seems warranted. 
The first optimisation would of course be to switch patients who are not doing well to 
another biological. Another form of treatment optimisation, however, could be lowering 
the dose or stopping infliximab in patients in whom infliximab is either given in too high 
a dose, or in whom the drug is no longer effective . Indeed, stop or dose reduction studies 
have shown that this is feasible in a large proportion of patients. 10"12 lt would however 
be very helpful when successful dose reduction or stopping could be predicted in these 
patients, to prevent unnecessary flares. Such a predictor is however not yet available. 
Several recent studies also demonstrated the potential use of mon itoring of 
pharmacokinetics during the maintenance phase of infliximab treatment in RA patients, 
next to the initiation phase. 13-16 Therefore, an interesting possible predictor for successful 
dose tapering could be infliximab serum trough levels and anti -infliximab antibody levels. 
lt can be conceived that patients with very high serum trough l1?vels of infliximab could be 
carefully dose reduced, and that on the other hand patients without detectable infliximab 
trough levels (or anti-infliximab antibodies) could even stop the drug without deterioration 
of disease activity. However, there is not much data on the potential value of measuring 
serum trough levels and anti-infliximab antibodies to guide infliximab treatment in daily 
cl inical practice during the maintenance phase. Therefore, to g1?t insight in the prevalence 
and course of infliximab serum trough levels and anti-infliximab antibodies in patients with 
low disease activity, we conducted a prospective observational longitudinal cohort study 
focussing on two research questions: 1) What is the prevaleno? of high, or low/no serum 
infliximab trough levels in patients with low disease activity? :2) Are these serum trough 




Patients and measurements 
All RA patients treated for at least 6 months (maintenance phase) with infliximab in daily 
clinical practice at the Sint Maartenskliniek, Nijmegen, the Netherlands, were included in a 
longitudinal observational cohort during a 1.5 year period or until treatment was discontinued. 
Enrolment of patients in this dynamic cohort started in February 2007. All patients received 
3mg/kg, with infusion intervals varying from 4-12 weeks. Decisions on interval variation were 
made by the treating rheumatologist who was blinded for the results of the serum trough 
levels and anti-infliximab antibodies, but according to local treatment protocol a DAS28 was 
measured every visit and rheumatologists were advised to shorten the interval or change 
therapy if the DAS28 was more than 3.2 during 2 visits or lengthen the interval if the DAS28 
was less than 2.6 during at least half a year. According to local protocol intervals were allowed 
to vary between 4-12 weeks. At every visit immediately before infusion sera were collected. 
Serum trough levels and anti-infliximab antibodies were measured as described elsewhere in 
one batch after the study had ended6 .7 Low levels were defined as< 1.0mg/L and high levels 
as> S.Omg/L. Both cut-offs are in accordance with previous reported t hresholds6 
Approval from the Medical Research Ethics Committee (MREC) was sought for. The 
committee decided that this approval was not necessary because DAS28 guided dose 
adaptation was performed as usual care for all patients meeting the requirements of the 
Dutch legislation and no extra-venous puncture was necessary. Informed consent for the 
extra blood sample and use of medical and demographic data was obtained from all patients. 
Statistical analyses 
Descriptive statistics were provided using mean (+/- standard deviation (SD)) or median 
(interquartile range(IQR)) values depending on the (non-) parametric distribution of measured 
patient characteristics. We explored our data by describing the following variables at study 
enrolment: prevalence of remission (defined as DAS28~ 2.6), low (DAS28~ 3.2) and high 
(DAS28> 3.2) disease activity state, low(< 1.0mg/L) and high (> S.Omg/L) infliximab serum 
trough levels and presence of anti -infliximab antibodies 6 ·7 Also the percentage of visits 
with low disease activity and remission was described. Additionally, the preva lence of low 
serum trough levels and anti-infliximab antibodies was confirmed in a subgroup of patients 
wit h long duration of stable low disease activity, defined as a DAS28~ 3.2 for at least 3 
consecutive visits. Furthermore, the course of anti- infliximab antibodies during follow up was 
investigated longitudinally. The influence of an increase in interval on anti-infliximab antibody 
occurrence and the influence of a shorter interval on anti-inflixirnab antibody disappearance 
were analysed by means of relative risk ratios (RR). Concomitant methotrexate (MTX) use was 
taken into account in the analysis using relative risk ratios as well. 
Finally, we also aimed to establish within-patient reliabi lity of infliximab serum trough levels 
and anti-infliximab antibodies. To investigate this, infliximab serurn trough levels measured at 
2 consecutive visits in patients with stable DAS28 and stable treatment were compared with 
a Wilcoxon test and a spearman correlation test. Furthermore, mean difference and limits of 
agreement (LoA) were calculated. 17 The reliability of ant i-infliximab antibodies was determined 
by kappa test statistic. All analyses were done with STATA 10. 1 statistical software. 
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RESULTS 
Patient characteristics and infliximab serum trough levels 
In total 1320 visits in 147 patients treated with infliximab for at least 6 months were 
collected in the observation period. Demographic data at study enrolment are depicted in 
Table 1. In 27% (95% confidence interval (Cl)= 20-34%) and 44% (95% Cl= 36-52%) of 
the patients the DAS28 was below 2.6 or 3.2 respectively. As demonstrated in table 2, at 
study enrolment. low infliximab serum trough levels are prevalent in patients with DAS28> 
3.2 (48%, 95% Cl= 37-59), but interestingly enough also in patients with low disease 
activity (3 1 %, 95% Cl= 20-42). In 14% of the patients with low DAS28 and in 21% of the 
patients with high DAS28 high infliximab serum trough levels were found (see Table 2). 
Low infliximab serum trough levels in patients with long term low disease activity 
Since at study enrolment a relatively high percentage of low inf liximab serum trough I E~vel 
was found in patients with low disease activity, we examined whether the presence of 
low serum trough levels was persistent in patients with stable low disease activity. During 
follow-up of 1.5 years 68 patients complied with the criterion of having a stable DAS28< 
3.2 during at least 3 visits. Indeed we found that 34% (95% Cl= 23-46%) of the patie·nts 
in this subgroup had consecutively low trough levels, with 41% of them showing anti-
infliximab antibodies. Mean infusion interval in these patients was 8.1 weeks (sd 2.05) and 
no interval changes occurred. 
Table 1. Baseline characteristics of all patients in the follow up cohort. 
Number of patients 
Age, years (mean, sd) 
Female, n (%) 
Weight, kg (mean, sd) 
Disease duration, years (mean, sd) 
RF positive, n (%) 
Anti -CCP positive, n (%) 
DAS28 at inclusion (mean, sd) 
Interval duration at inclusion, weeks (median, p25-75) 
Previous DMARDs, weeks (median, p25-75) 
Concomitant DMARD use, n (%) 
Concomitant MTX use, n (%) 
Previous anti-TNF-alpha therapy, n (%) 














2.5 (2 .0) 
sd= standard deviation; n= number; RF= Rheumatoid Factor; Anti-CCP= Anti-Cyclic Citrullinated 
Protein; DAS28= Disease Activity Score of 28 joints; p25-75= interquartile range from 25 to 7~>%; 
DMARD= Diseases Modifying Anti-rheumatic Drug; MTX= methotrexate; TNF= Tumour Necrosis Fa.ctor 
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Table 2. Percentage of low and high infliximab serum trough levels and presence of anti-
infliximab antibodies in patients with low and high DAS28 at the first study visit. 
No infliximab Low* Intermediate* High** Anti-
serum infliximab infliximab infliximab infliximab 
trough level trough levels trough levels trough levels antibodies Total 
DAS28 % (95% Cl) % (95% Cl) % (95% Cl) % (95% Cl) % (95% Cl) N patients 
< 2.6 13 (2-23) 23 (1 0-35) 48 (32-63) 18 (6-29) 13 (2-23) 40 
~ 3.2 13 (4-20) 18 (9-28) 55 (43-67) 14 (5-22) 11 (3-19) 65 
> 3.2 29 (1 9-39) 18 (1 0-27) 32 (22-42) 21 (12-30) 29 (19-39) 82 
DAS28= Disease Activity Score of 28 joints; Cl= confidence interval;* Low serum trough levels are 
defined as< l.Omg/L;** High serum trough levels are defined as> S.Omg/L 
Presence of anti-infliximab antibodies 
Anti-infliximab antibodies were found in 18% of all 1320 visits (95% Cl = 16-20) and 
49 of the 147 RA patients (33%, 95% Cl= 26-41 ) had anti -infliximab antibodies at least 
once during follow up. There was no significant association between MTX use and anti-
infliximab antibodies as calculated by RR (0.75, 95% Cl= 0.47-1.21, p= 0.25). In 22 
out of 49 patients (45%) anti-infliximab antibodies were persistently found every visit. 
These patients had a median observation period of 58 weeks (IQR: 8-74) and a mean 
DAS28 of 3.2 (sd1.2). During follow up, 14 of the patients with anti-infliximab antibodies 
discontinued infliximab for the following reasons: ineffectiveness (n= 10, n= 2 also had 
an allergic reaction), allergic reaction (n= 1 ), malignant disease (n= 1 ), pregnancy wish 
(n= 1 ), other side effect (n= 1 ). In contrast 26 patients without anti-infliximab antibodies 
discontinued of whom 16 because of ineffectiveness. 
There were 27 patients with intermittent anti-infliximab antibodies (median of 3 
subsequent visits (IQR: 1-7)). The RR for the emerging of anti-infliximab antibodies a·fter 
interval increase was 5.2 (95% Cl 2.6-1 0.7, p< 0.0001). After interval decrease the RR for 
disappearing of anti-infliximab antibodies was 4.9 (95% Cl 2.5-9 .4, p< 0.0001). Interval 
changes occurred in 235 of the 1320 visits, of which 125 were interval increases. In 11 
visits the interval increase was followed by HACA emergence. Interval decreases occurred 
in 110 visits, w ith subsequent disappearance of anti-infliximab antibodies in 12 visits. 
Reliability of infliximab serum trough leve ls and anti-infliximab antibodi es 
A small and non-significant mean difference in trough levels was found between two 
consecutive visits in patients with stable DAS28 and treatment (-0.26, p= 0.38), w ith 
relatively small LoA of -3 .6 to 3.11 . When considering serum trough levels in the re levant 
range of 0-5mg/L, LoA were even smaller (-0.9 - 0.8), with a mean difference of -0.04. 
Agreement between serum trough levels analysed by spearman correlation was 0 .97 
(p= 0.00001, figure 1 ). For anti-infliximab antibodies the correlation between subsequent 
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Figure 1_ Serum trough levels measured at 2 consecutive visits in RA patient s with stable 
DAS28 and infliximab dosing. 
DISCUSSION 
In our prospective observational longitudinal cohort study of RA patients t reated with 
infliximab in the maintenance phase we encountered several interesting f indings 
concerning the relation between disease activity, infliximab serum trough levels and anti -
infliximab antibodies, and the influence of treatment interval changes. 
First of all , low infliximab serum trough levels (with/without anti-infliximab antibodies) 
are prevalent in w ell-controlled RA patients treated with infliximab during the maintenance 
phase (about 1/3 of the pat ients). Since most articles on serum t rough levels and anti -
infliximab antibodies are describing the relation between low levels and non-response 
and high levels and good-response, this might seem a counterintuitive result. Nevertheless 
when examining these other studies one can also appreciate that a considerable proport ion 
of patients with good response or low DAS28 has no measurable trough level of infl iximab 
or have anti-infliximab antibodies (for example Pascuai-Salcedo et al also described that 
24% of EULAR good-moderate responders to infliximab had anti -infliximab antibodies)B 
Pondering on these find ings it could be hypothesised that the low disease activity in these 
patients might not be attributed to infliximab. The initial response of infliximab in the 
induction phase of the t reatment in these patients could be explained by a temporary 
need for infliximab, placebo response, regression to the mean or effects of eo-medication. 
There are some counterarguments against this line of reasoning. One could argue, 
for example, that the infliximab effect is (partially) determined by peak levels or t ime 
integrated area under the curve (AUC) rather than by minimal inhibitory concentration 
(MIC). This seems unlikely as subcutaneous anti-TNF agents d•emonst rate similar efficacy 
compared to int ravenous anti -TNF without peak levels. 18 Also, it could be conceived that 
low infliximab serum levels and anti-infliximab antibodies just before the next infusion 
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isn't a good proxy for low serum levels or anti-infliximab antibodies during the majority 
of the treatment interval. However, Van den Bemt et al demonstrated that anti-infliximab 
antibodies at the end of the interval are strongly associated with anti-infl iximab ant ibodies 
or low/non-measurable serum levels in between infusions, indicating that low or no 
infliximab exposure was present during most of the treatment interval. 19 Nevertheless, 
whether RA patients with low infliximab serum trough levels can really de-esca late or stop 
treatment needs confirmation by means of an intervention study. Of note, high infl iximab 
serum trough levels also occur relatively frequent. This may identify patients in whom the 
infliximab dose can be reduced whilst maintaining clinical efficacy. 
A second finding was that reliability for consecutive measurements of serum trough levels 
and anti-infliximab antibodies of both infliximab levels and anti-infliximab antibody status was 
found to be very high . Reliable measurements are essential be·fore considering measuring 
infliximab serum trough levels and anti-infliximab antibodies in daily clinical practice. 
With regard to the anti-infliximab antibodies it should be noted that, although one-
third of the patients had detectable antibodies during at leas;t one visit, in only half of 
these patients they were found consistently every visit. Since the level of anti-infliximab 
antibodies is the resultant of antibody formation and (antigen-bound) antibody clearance, 
a change in infusion interval (thus a change in antigen challenge) might explain why in 
some patients anti-infliximab antibodies were only temporarily measurable. Indeed, after 
increasing the infusion interval anti-infliximab antibodies were found more frequent ly 
as can be concluded based on the RR. However, we have shown that. although anti-
infliximab antibody status might change, most of these patients still have very low serum 
infliximab trough levels in between visits without antibodies. In addition our data fai led 
to confirm the relationship between methotrexate use and reduced occurrence of anti-
infliximab antibodies, wh ich could well be due to a lack of statistical power3 
Finally, our study confirmed earlier data that adequate disease control in daily cl inical 
practice is often not reached, as demonstrated by less than half of the patients having a 
DAS28 below or equal to 3.2. Although the effect of tight control is well establ ished and a 
local protocol encouraged and facil itated physicians to change treatment if disease activity 
was inadequately controlled, still half of the patients didn't reach the treatment target.2°·21 
This finding, that is concordant with findings in other biologic cohorts, underscores the n1?ed 
for better implementation strategies in daily clinical practice of tight control based treatment. 
In conclusion, our study demonstrated that measuring infliximab serum trough levels 
and ant i-infliximab antibodies during the maintenance phase of infliximab treatment could 
be of va lue to optimize treatment. Low (and to some extent high) infliximab serum trough 
levels are prevalent in RA patient s treated for a longer period of time with infl iximab, 
also in patients with low disease activity. Since infliximab serum trough levels and anti-
infliximab antibodies are rel iable measurements, these might be used to identify patients 
in whom infliximab can be de-escalated or stopped. 
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To evaluate the predictive value of (anti)infliximab trough levels for successful infliximab down-
titration or discontinuation is analysed in established rheumatoid arthritis (RA) patients. 
Methods 
In RA patients treated with infliximab with stable DAS28 < 3.2 and stable RA treatment for 
> 6 months, infliximab was down titrated with 25% of the original dose (3mg/kg) every 
8-12 weeks until discontinuation or flare . Patients were followed for a year. At start of 
down-titration infliximab serum trough level and anti-infliximab antibodies were measured 
with an enzyme-linked immunosorbent assay and a radioimmunoassay respectively. 
Levels were categorised as low(< 1.0 mg/1), normal (1.0- 5.0 mg/1) and high(> 5.0m~J/I). 
Sensitivity and specificity of low, normal and high levels at start of down-titrat ion were 
calculated for prediction of successful infliximab discontinuation, impossibi lity to stop 
treatment and successful partly down-titration respective ly. The same analysis was done 
for anti-infliximab antibodies and discontinuation. 
Results 
In 51 RA patients infliximab was down-titrated: 8 could stop, in 22 the dose was part ly 
down-titrated and 21 returned to baseline dose. Sensitivity and specificity of low trough 
levels for successful discontinuation was 50% (95% confidence intervai(CI)= 16-84) and 
56 (95% Cl= 40-71), for high levels and partial down-titration 26% (95% Cl= 10-48) and 
82% (95% Cl= 63-94) and for anti-infliximab anti-bodies and discontinuation 13% (9'3% 
Cl= 3-53) and 84% (95% Cl= 69-93) respectively. 
Conclusion 
Predictive value of (anti-)infliximab serum trough levels for successful down-titration or 
discontinuation of infliximab in established RA patients with stable low disease activity 




Treatment of rheumatoid arthritis (RA) has changed from a gradual step up regimen to a "hit 
early" and "hit hard" strategy with prompt initiation of disease modifying anti-rheumatic 
drugs (DMARD), t ight disease control and distinct, quantifiable treatment goals. Several 
studies have already demonstrated superiority of this hit-hard-and-hit-early strategy to 
routine outpatient care in RA. 1-8 However, this strategy may lead to overtreatment. which 
raises a concern when considering dose-related side effects and, especially with biologic 
treatment, considerable costs 9 -16 One of the biologic treatment options in RA is infliximab. 
Efficacy has been demonstrated in several pivotal randomised controlled trials, but it is 
also associated with increased risk of severe adverse events, like infections. 12· 14· 15•17•19 In 
addition, it is an expensive treatment, which poses a concern in current financial times. 
To prevent overtreatment with infliximab, treatment could be down-titrated 
or discontinued in RA patients with stable low disease activity, which is feasible as 
demonstrated by several studies. 20-26 A downside t o down-titration or discont inuat ion is 
the occurrence of f lares, which is associated with radiologic damage and reduced quality 
of life and function n Identification of patients in whom the dose cannot be reduced 
would therefore be very helpful. On the other hand, if it is possible to identify patients 
in whom immediate infliximab discontinuation is feasible, a time consuming down-
titration regimen can be skipped. Therefore a predictor for successful down-titration and 
discontinuation of infliximab is warranted. 
A possible predictor for successfu l dose tapering could be using infliximab serum 
trough levels and anti-infliximab antibody levels, for the following arguments: first of all, 
there is an association between infliximab trough levels and/or anti-infliximab antibodies 
and clinical effect as demonstrated in several cross-sectional and longitudina l studies. 28-34 
Secondly, serum trough levels demonstrate a large interindividual variability in RA patients 
with long term infliximab treatment, which is one of the prerequisites for therapeutic drug 
monitoring (TDM) 3 5 In about 30% of RA patients with stable low disease activity and long 
term infliximab treatment low infliximab serum trough levels (less than 1.0 mg/1) were found 
and in about 15% of these patients high (more than 5.0 mg/1) levels36 Finally, infliximab 
serum trough level and anti-infliximab concentrations are stable in subsequent visits in 
patients with stable disease activity and infliximab treatment. an essential requirement for 
TDM.36 Subsequently, as also described by Bendtzen et al and K.rieckaert et al, a treatment 
algorithm in patients with low disease activity can be proposed: patients with low disease 
activity having low infliximab serum trough levels or detectable anti -infliximab-antibodies 
can discontinue infliximab since it might not be responsible for the maintenance of low 
disease, and patients with low disease activity and very high infl iximab serum trough levels 
might be able to dose reduce 37-39 
To further explore the abovementioned hypotheses we have measured trough (anti-) 
infliximab levels in established RA patients who were included in a prospective cohort study 
investigating down-titration and discontinuation . Here we describe the test characteristics 
(sensitivity/specificity) for the predictive value of 1) low infliximab levels or presence of 




All RA patients (fulfilling the ARA criteria 1987) of the Sint Maartenskliniek Nijmegen, The 
Netherlands, a hospital specialized in Orthopaedics, Rheumatology and Rehabilitation, 
treated with infliximab and with stable low disease activity and stable anti-rheumatic 
treatment were treated following a standardized down-titration protocol. Only patients w ith 
a Disease Activity Score 28 (DAS28) less than 3.2 (in accordance with previous infliximab 
discontinuation studies) for at least 6 months were eligible for the down-titration protocol. 22;4° 
According to the down-titration protocol infliximab dose was tapered down with 2'5% 
of the original dose, which was 3mg/kg, every 8 -12 weeks without changing the interval 
unti l discontinuation or flare 26 A validated DAS28-based flare was used to decide on 
reinstating therapy or dose-increasing.41 Patients were seen by a physician before every 
infusion and were encouraged to contact the rheumatologist, if to their opinion, disease 
activity had deteriorated. If a patient flared, infliximab dose was increased to the last 
effective dose. If despite increasing the dose DAS28 remained more than 3.2, the dose 
was further increased with a maximum of 3mg/kg. If disease activity persisted a different 
biologic or DMARD was in itiated. 
From January to April201 0, all RA patients who started with infliximab down-titration 
were included in an observational cohort. Each patient was followed for 1 year. At start 
of down-titration demographic data including gender, age, weight, disease duration, 
rheumatoid factor, anti-cyclic citrullinated protein (Anti-CCP), erosive disease, previous 
and concomitant DMARD use, previous biologic treatment, concomitant NSAID treatment, 
duration of infliximab treatment and employment were collected. Every visit DAS28, 
infliximab serum trough levels and/or anti-infliximab antibodiPs levels and change in RA 
medication (DMARD, NSAID, corticosteroid) were assessed 2 6 
lnfliximab and anti-infliximab-antibody levels in serum were determined by an enzyme-
linked immunosorbent assay (ELISA) and a radioimmunoassay (RIA) respectively, described 
in detail elsewhere (Sanquin Research, Amsterdam, The Netherlands).28·29 These assays were 
chosen since an association between clinical effect and respectively trough levels measured 
with the ELISA and anti -infliximab-antibodies with the RIA has been demonstrated 
previously.28•29A 2 Trough levels below 1.0 mg/1 were classified as low levels, between 1.0 
and 5.0 as normal levels and serum trough levels of more than S.Omg/1 were defined as 
high. Anti-infliximab-antibodies were measured with the lower I imit for a positive result set 
at 12 Arbitrary Units (AU)/ml, also described in detail elsewhere28 The cut-off points for 
serum t rough levels and anti-infliximab-antibodies are concordant with previous publ ished 
studies.28•29•33•42 Since all serum trough levels and anti -infliximab antibodies were measured 
in batch afterwards, physicians were unaware of the trough levels or antibody status of 
patients during the year of follow up. Two samples per patient and per visit were stored 
(vial a and via l b). Afterwards both samples were measured consecutively to assure w ithin-
patient-reproducibility of serum infliximab and anti-infliximab IPvels. 
All RA patients included in our cohort had high disease activity at initial start of 
infliximab treatment and had been treated with at least two DMARDs, one of which had 
to be methotrexate, as is obliged by Dutch reimbursement guidelines. In addition, this 
observational study did not require approval of an ethical committee accord ing to Dutch 
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legislation since DAS28 guided dose down-titration was performed as usual care for all RA 
patients, infliximab serum trough level and anti-infl iximab antibody measurement re qui red 
no extra venous puncture and no demanding questionnaires were administered. Written 
informed consent was given by all patients. 
Statistics 
Descriptive statistics were used for demographic data and percentages of patients in 
whom infliximab was stopped, partly down-titrated or remained the same as before down-
titration . Agreement between infliximab and anti-infliximab levels measured in via l a and b 
was verified with intraclass correlation coefficient (ICC). Differences in serum t rough levels 
between patients in the groups 'infliximab discontinuation', 'partly down-titrated' and 'no 
down-t itration ' (in other words: infliximab dose returned to the same level as at before 
down-titration) was tested by means of the kruskal wall is nonparametric procedure. 
Primary outcome was sensitivity and specificity of the three categories low, high and 
normal trough levels at start of down-titration for predicting 'infliximab discontinuation, 
'partly down-titrated' and 'no down-titration'. In addition receiver-operator-curves (ROC) 
were created for successful infliximab discontinuation and for successful infliximab down-
titration to verify the predefined cut-off va lues for low and high trough levels. Sensitivity 
and specificity of the presence of anti-infl iximab-antibodies at start of down-titration for 
predicting infliximab discontinuation was determined. 
RESULTS 
At the start of the study in our cl inic 94 RA patients were treated with infliximab and 
considered for el igibility for the study. Fifty-one of these patients met the criteria of the 
down-tit ration protocol and were included in our prospective cohort. Demographic data 
of these patients is summarized in table 1. Concomitant methotrexate treatment was 
prevalent (68%). Most patients had long standing RA, as demonstrated by the median 
disease duration of 12 years. The median treatment interval was every 8 weeks [IQR 6-8]. In 
our cohort 16% (95% confidence interval (Cl)= 6-26) of the patients could stop infliximab 
treatment after 1 year, 45% (95% Cl= 31 -59) could successfull)t partly down-titrate and in 
39% (95% Cl= 26-53) the dose was the same compared to ba:seline. The mean DAS28 at 
flare visits was 4.3 (sd= 0.96), with all components of the DAS28 demonstrating an increase. 
The ICC between serum trough levels measured in vial a and b was high (r2= 1.0, 
p< 0.00001 ). Of the 51 patients in our cohort 23 had a low infliximab serum t rough level 
at the start of down-titration (45%, 95% Cl= 31 -59%), 17 had levels between 1.0 mg/1 
and 5 mg/1 (33%, 95% Cl= 20-46) and 11 had high infliximab serum trough levels (22%, 
95% Cl=1 0-33). Of the 23 patients with low serum infliximab trough levels eight (16% 
of all patient s, 95% Cl= 6-26) had anti-i nfliximab-antibodies . Of these 8 patients, 7 
were treated with concomitant DMARDs (methotrexate, leflunomide or azathioprine). 
There was no statistically significant difference in serum trou~Jh levels between patients 
in the groups 'infliximab discontinuation', 'partly down-titrated' or 'no down-titration' 
(p= 0.18), with median serum trough levels of 1 .0 (IQR 0.3- 1. 1 ), 1. 7 (IQR 0.54-5.1) and 
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Table 1. Patient characteristics. Mean and standard deviation (sd) are given, unless 
specified otherwise. 
Number of patients 
Age, years (sd) 
Female, n (%) 
Weight, kg (sd) 
Disease duration in years, median [p25-p75] 
RF positive, n (%) 
Anti-CC P positive, n (%) 
Erosive disease, n (%) 
DAS28 at inclusion (sd) 
Duration of infliximab therapy, years (sd) 
Interval duration at start in weeks, median [p25-p75] 
lnfl iximab dose at start, mg (sd) 
lnfl iximab at start, mg/kg (sd) 
N of previous DMARDs, median [p25-p75] 
Previous MTX, n (%) 
Previous anti-TNF-alpha therapy, n (%) 
Concomitant DMARD use, n (%) 
Concomitant MTX use, n (%) 
Concomitant corticosteroid use, n (%) 
51 


















sd= standard deviation; n= number; p25-75= interquartile range from 25 to 75%; RF= Rheuma-
toid Factor; Anti-CCP= Anti-Cyclic Citru llinated Protein; DAS28= Disease Activity Score of 28 joints; 
DMARD= Diseases Modifying Anti-rheumatic Drug; MTX= methot rexate; TNF= Tumour Necrosis 
Factor; NSAID= Non-Steroidal Anti-Inflammatory Drug 
0.55 (IQR 0.03-2.35) respectively. In table 2 the percentage of low, normal and high 
serum trough levels and anti-infliximab antibodies at start of down-titrat ion in the groups 
' infliximab discontinuation', 'partly down-t itrated' and 'no down-t itrat ion' is described. 
Sensitivity and specificity analyses for the different categories of infliximab serum 
trough levels and anti-infliximab antibodies at start of down-titration are demonstrated 
in table 3. Having low-to-non-measurable infliximab serum trough levels has a sensitivity 
of 50% (95% Cl= 16-84) and specificity of 56% (95% Cl= 40-71) for identifying patients 
who can stop infliximab t reatment, resulting in a positive predictive value of low levels 
for successful infliximab discontinuation of 17% (95% Cl= 5-39) and negative predic tive 
value of 86% (95% Cl= 67-96). High infliximab through levels were also not predictive 
for successful partly down-t itrat ion, with sensitivity of only 26% (95% Cl= 1 0-48), and 
specificity of 82% (95% Cl= 63-94). Finally anti -infliximab-ant ibodies at the start of down-
titration are also not predictive of successful infl iximab discontinuation, with sensitivity of 
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Table 2. Percentage of infliximab discontinuation and down-titration divided by inflixirnab 
trough level category and anti-infliximab antibodies. 
Category infliximab 
serum trough level 
Low IFX trough level" 
High IFX trough level .. 
NormaiiFX trough level 
Anti-infliximab antibodies 
IFX Partly No 
discontinuation down-titrated down-titration Number of 
% (95 % Cl) % (95% Cl) % (95 % Cl) patients 
17 (2-33) 30 (12-49) 53 (32-73) 23 
18 (0-36) 59 (35-82) 24 (3-44) 11 
9 (0-26) 55 (25-84) 36 (8-65) 17 
12.5 (1 -35) 12 .5 (1 -35) 75 (45-100) 8 
IFX= infliximab; * lnfl iximab trough level of< l.Omg/1; ** lnfliximab trough level of> 5.0 mg/1 
Table 3. Sensit ivity and specificity for different trough level categories and anti-infliximab-
antibodies and down-titration or discontinuation. 
Sensitivity Specificity 
% (95% Cl) % (95 % eo 
Low IFX trough level" IFX discontinuation 50 (16-84) 56 (40-71) 
High IFX trough level"" Partly down-titrated 26(1 0-48) 82 (63-94) 
Normal IFX trough level No down-titration 20 (6-44) 58 (39-75) 
Anti-infliximab anti-bodies··· IFX discontinuation 13 (3-53) 84 (69-93) 
IFX= infliximab; * lnfliximab trough level of< l.Omg/1 * * lnfliximab trough level of> 5.0 mg/1; * ** 
Lower limit of measurable anti-infliximab-antibodies is < 12U/I 
13% (95% Cl= 3-53) and specificity of 84% (95% Cl= 69-93). In addition ROC curves for 
predicting successful infl iximab discontinuation and down-titration with different cut off 
levels for infliximab serum trough levels are demonstrated in figure 1. The area under the 
curves (AUC) was 0.44 for discontinuation, and 0.65 for partly down-titration. 
DISCUSSION 
In our cohort study no predictive value of infliximab serum trough levels was found for 
successful infl iximab discontinuation or down-titration. The previously proposed hypotht?sis 
that RA patients with stable low disease activity and low serum trough levels could often 
stop infliximab treatment was not therefore confirmed, nor was the hypothesis that most 
patients with high levels could partly down-titrate37· 39 The same was, perhaps su rprisingly, 
true for patients with anti-infliximab antibodies; they could not stop infliximab more 
frequently than patients without anti -infliximab antibodies. 
The internal validity of our study seems adequate. The design is the preferred design 
for a prediction study, with intervention, longitudinal follow-up and assessment of the 
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Figure 1. ROC curves for infliximab level as predictor of successful discontinuation (A) and of 
successful down-titration (B). 
sample of long-term successful TNF blocker-using RA patients. In our cohort , patients 
have a somewhat longer disease duration than in most down-titration studies, since these 
also included induction studies. 21 ·22•24•43 These latter studies, of which the BeSt study is 
an example, are however not representative to the average Dutch (and internationa l) 
RA population, since biologies are reserved as a second line treatment. In addition, both 
the used flare criterion and the (anti)infliximab serum test have been previously used and 
validated23.29.4 1.45 Finally, due to the limited number of pat ients it could be argued that 
there is a precision problem. With in the confidence intervals, however, our resu lt results 
can be evaluated, and follow-up t ime was ample, which impl iies that the possibility that 
our main f inding is resu lt of a type 11 error seems unlikely. 
Our results, however, leaves us with an awkward feeling, as it seems counterintu itive 
that (anti)infliximab serum trough levels are not informative at all for the optima l dose of 
infliximab in a patient. This is especially true for the f inding that presence of anti-infl iximab 
antibodies does not translate into a higher percentage of successful discontinuation. 
Pondering on the possible underlying explanations for our, possibly, disappointing results , 
several can be hypothesized. 
Firstly, the test we used may not measure the construct we wanted to measure: the 
presence of (anti) infliximab. The reproducibil ity of the tests (the ELISA and the RIA) has 
been confirmed and it has been verif ied that the tests measure indeed only (anti-)infliximab 
levels. 29·29.44 However. the ELl SA we used measures infliximab but does not detect infliximab 
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bound to TNF-o: in vivo or to anti-infliximab antibodies. Thus, the levels we measured only 
constitute the unbound fraction of the drug in the circulation. Therefore, it is conceivable 
that two scenarios contribute in an opposite direction, negating any predictive value: part 
of the patients has low trough levels due to consumption of infliximab by high circulating 
TNF alpha levels (effective infliximab), and part of the patients has low levels, due to for 
example antibodies, but have low disease activity irrespectiv12 of infliximab (ineffective 
infliximab). This problem could be circumvented by the use of tests that measure total 
(bound and unbound) infliximab. Of note, the tests we used are commercially available, 
have extensively been validated and are cross-sectionally associated with clinical effect. 
Another problem with anti-infliximab antibodies could be that the RIA used to measure 
anti-infliximab antibodies only binds to the Fab fragment of infli;<imab, leaving the question 
what role anti-infliximab-antibodies not binding to the Fab fragment play unanswered. lt 
can also be argued that the antibodies measured are low-affinity antibodies with no in 
vivo relevance. However, for both the ELISA and the RIA we used, it has been previously 
described that there is an association between cl inical effect and (anti)infliximab serum 
trough levels (low levels and/or antibodies were associated with less efficacy). 
Secondly, it could be a problem of wrong time or place. The choice of trough level timing 
is based on the premise that the minimal-inhibitory-concentration (MIC) of infliximab is 
responsible for the effect, but maybe AUC or peak levels are the determinant for efficacy. 
This argument however is countered by the fact that subcutaneous TNF-blockers with 
much lower peak levels are equally effective.45 Also, van den Bemt et al demonstrated that 
patients having trough anti-infliximab antibodies also have low infliximab levels or already 
anti-infliximab antibodies in the middle of the infusion interval, suggesting long duration 
of non-exposure to infliximab42 With regard to wrong place, it could be suggested that 
infliximab is effective in a different compartment (such as synovial flu id) than serum. This 
seems unlikely since infliximab, as other antibodies and large proteins, wi ll follow the osmotic 
gradient, assuming that the synovial compartment is reached due to active inflammation 
with subsequent fenestration. Therefore, the serum- synovial compartment gradient should 
always be greater than one. Finally, although patients in our cohort have stable infliximab 
interval duration, there are inter-individual differences in intervals. Since interval duration wi ll 
have an effect on infliximab serum trough levels, this wil l influence the results. Then again, 
all our patients had stable intervals during at least 6 months indicating stable infliximab 
serum trough levels. Ideally of course, a larger cohort could analyse separate ROC curves per 
interval duration. Of note, when only the patients with intervals of 8 weeks were ana lysed 
results were comparable, although as expected with larger confidence intervals. 
To summarize, although we are aware of several possible explanations for 
our disappointing results, we were unable to predict successful down-titration or 
discontinuation of infliximab in a typical RA cohort as has been proposed in published 
algorithms on how to use TDM of TNF-blockers in patients with stable low disease activity 
in daily clinical practice with the (anti-)infliximab tests we used. Future research is needed 
to explore whether serum levels and presence of anti-drug antibodies of other biologies 
are capable of predicting successful down-titration in RA, and also to focus on other 




1. Knevel R, Schoels M, Huizinga TW, Aletaha 
D, Burmester GR, Combe B et al. Current 
evidence for a strategic approach to the 
management of rheumatoid arthritis with 
disease-modifying antirheumatic drugs: 
a systematic literature review informing 
the EULAR recommendations for the 
management of rheumatoid arthritis. Ann 
Rheum Dis 201 0; 69(6):987-94 
2. Allaart CF, Goekoop-Ruiterman YP, de Vries-
Bouwstra JK, Breedveld FC, Dijkmans BA. 
Aiming at low disease activity in rheumatoid 
arthritis w ith initial combination therapy or 
initial monotherapy strategies: the BeSt 
study. Clin Exp Rheumatol2006; 24(6 Suppl 
43):S-82. 
3. Bakker MF, Jacobs JW, Verstappen SM, 
Bijlsma JW. Tight control in the treatment of 
rheumatoid arthritis: efficacy and feasibility. 
Ann Rheum Dis 2007; 66 Suppl3:iii56-iii60. 
4. Fransen J, Moens HB, Speyer I, van Riel PL. 
Effectiveness of systematic monitoring of 
rheumatoid art hritis disease activity in daily 
practice: a mult icentre, cluster randomised 
controlled trial. Ann Rheum Dis 2005; 
64(9): 1294-8. 
5. Goekoop-Ruiterman YP, de Vries-Bouwstra 
JK, Kerstens PJ, Nielen MM, Vos K, van 
Schaardenburg D et al. DAS-driven therapy 
versus rout ine care in patients with recent-
onset active rheumatoid arthritis. Ann 
Rheum Dis 201 0; 69(1 ):65-9. 
6. Grigor C. Capell H, Stirling A, McMahon AD, 
Lock P, Valiance R et al. Effect of a treatment 
strategy of tight control for rheumatoid 
arthrit is (the TICORA study): a single-blind 
randomised controlled trial. Lancet 2004; 
364(9430):263-9 
7. Korpela M, Laasonen L, Hannonen P, 
Kautiainen H, Leirisalo-Repo M, Hakala 
M et al. Retardation of joint damage in 
pat ients with early rheumatoid arthritis by 
initial aggressive treatment with disease-
modifying antirheumatic drugs: f ive-year 
experience from the FIN-RACo study. 
Arthritis Rheum 2004; 50(7):2072-81. 
8. Tanaka E, Mannalithara A, lnoue E, Hara 
M, Tomatsu T, Kamatani N et al. Efficient 
management of rheumatoid arthritis 
significantly reduces long-term functional 
disability. Ann Rheum Dis 2008; 67(8): 1153-8. 
9. Askling J, van Vollenhoven RF, Granath F, 
Raaschou P, Fared CM, Baecklund E et al. 
Cancer risk in patients with rheumatoid 
arthritis treated with anti-tumor necrosis 
factor alpha therapies: does the risk change 
84 
with the t ime since start of treatment? 
Arthritis Rheum 2009; 60(11):3 180-9. 
10. Askling J, BongartzT. Malignancy and biologic 
therapy in rheumatoid arthritis. C urr Cl pin 
Rheumatol 2008; 20(3):334-9 [Review] 
11. Bongartz T, Warren FC, Mines D, Matteson 
EL, Abrams KR, Sutton AJ. Etanercept 
therapy in rheumatoid arthrit is and the risk 
of malignancies: a systematic review and 
individual patient data meta-analysis of 
randomised controlled trials. Ann Rheum 
Dis 2009; 68(7): 1177-83. 
12. Bongartz T, Sutton AJ, Sweeting MJ, Buchan 
I, Matteson EL, Montori V. Anti-TNF antibody 
therapy in rheumatoid arthritis and the risk 
of serious infections and malignancies: 
systemati c review and meta-analysis of rare 
harmful effects in randomized contro lled 
trials. JAMA 2006; 295(19):2275-85. 
13. Keystone EC. Does Anti-Tumor Necrosis 
Factor-{alpha} Therapy Affect Risk of 
Serious Infection and Cancer in Patients 
with Rheumatoid Arthritis?: A Rev iew 
of Longterm Data . J Rheumatol 2011; 
38(8):1552-62. [Review] 
14. Leombruno JP, Einarson TR, Keystone EC. 
The safety of anti-tumour necrosis factor 
treatments in rheumatoid arthritis: meta 
and exposure-adjusted pooled analyses 
of serious adverse events. Ann Rheum Dis 
2009; 68(7): 1136-45. 
15. Listing J, Strangfeld A, Kary S, Rau R, von 
HU, Stoyanova-Scholz M et al. Infections in 
patients with rheumatoid arthrit is treated 
with biologic agents. Arthritis Rheum 2005; 
52(11 ):3403-12 
16. Matteson EL, Bongartz T. Tumor necrosis 
factor antagonists and cancer in patients 
with rheumatoid arthritis. Nat Clin Pract 
Rheumatol 2007; 3(1): 14-5. 
17. Singh JA, Wells GA, Christensen R, Tanjong 
GE, Maxwell L, Macdonald JK et al. Adverse 
effects of biologies: a network meta-analysis 
and Cochrane overview. Cochrane Database 
Syst Rev 2011; 2:CD008794. [Review] 
18. Maini R, St Clair EW, Breedveld F, Furst 
D, Kalden J, Weisman M et al. lnfliximab 
(chimeric anti-tumour necrosis factor alpha 
monoclonal antibody) versus placebo in 
rheumatoid arthritis patients receiving 
concomitant methotrexate: a randomised 
phase Ill trial. ATIRACT Study Group. Lancet 
1999; 354(9194):1932-9. 
19. St Clair EW, van der Heijde DM, Smolen 
JS, Maini RIN, Bathon JM, Emery P et 
al. Combination of infl iximab and 
methotrexate therapy for early rheumatoid 
arthritis: a randomized, controlled trial. 
Arthritis Rheum 2004; 50(11 ):3432-43. 
20. van den Bemt BJ, den Broeder AA. Snijders 
GF, Hekster YA, van Riel PL, Benraad B et 
al. Sustained effect after lowering high-
dose infliximab in patients with rheumatoid 
arthritis: a prospective dose titration study. 
Ann Rheum Dis 2008; 67(12): 1697-701. 
21. Nawata M, Saito K, Nakayamada S, Tanaka Y. 
Discontinuation of infliximab in rheumatoid 
arthritis patients in clinical remission. Mod 
Rheumatol 2008; 18(5):460-4. 
22. Tanaka Y, Takeuchi T, Mimori T, Saito K, 
Nawata M, Kameda H et al. Discontinuation 
of infliximab after attaining low disease 
activity in patients with rheumatoid arthritis: 
RRR (remission induction by Remicade in RA) 
study. Ann Rheum Dis 201 0; 69(7): 1286-91. 
23. Brocq 0, Millasseau E, Albert C. Grisot C. 
Flory P, Roux CH et al. Effect of discontinuing 
TNFalpha antagonist therapy in patients 
with remission of rheumatoid arthritis. Joint 
Bone Spine 2009; 76(4)350-5. 
24. Klarenbeek NB, van der Kooij SM, Guler-
Yuksel M, van Groenendael JH, Han KH, 
Kerstens PJ et al. Discontinu ing treatment 
in patients with rheumatoid arthritis in 
sustained clinical remission: exploratory 
analyses from the BeSt study. Ann Rheum 
Dis 201 0; 70(8): 1389-94 
25. Saleem B, Nizam S, Emery P. Can remission 
be maintained with or without further drug 
therapy in rheumatoid arthritis? Clin Exp 
Rheumatol 2006; 24(6 Suppl 43):S-6. 
26. van der Maas A, Kievit W, van den Bemt BJ, 
van den Hoogen FH, van Riel PL, den Broeder 
AA. Down-titration and discontinuation of 
infliximab in rheumatoid arthritis patients 
with stable low disease activity and stable 
treatment: an observational cohort study. 
Ann Rheum Dis 2012; 71(11):1849-54. 
27. Welsing PM, van Gestel AM, Swinkels HL, 
Kiemeney LA, van Riel PL. The relationship 
between disease activity, joint destruction, 
and functional capacity over the course of 
rheumatoid arthritis. Arthritis Rheum 2001; 
44(9):2009-17 . 
28. Wolbink GJ, Vis M, Lems W, Voskuyl 
AE, de Groot E, Nurmohamed MT et al. 
Development of antiinfliximab antibodies 
and relationship to clinical response in 
patients with rheumatoid arthritis. Arthritis 
Rheum 2006; 54(3):711-5. 
29. Wolbink GJ, Voskuyl AE, Lems WF, de Groot 
E, Nurmohamed MT, Tak PP et al. Relationship 
between serum trough infliximab levels, 
TITLE 
pretreatment C reactive protein levels, and 
clinical response to infliximab treatment 
in patients with rheumatoid arthritis. Ann 
Rheum Dis 2005; 64(5):704-7. 
30. Bendtzen K, Cieborek P, Svenson M, Larsson 
L, Kapetanovic MC, Saxne T. Individualized 
monitoring of drug bioavai lability and 
immunogenicity in rheumatoid arthritis 
patients trea ted with the tumor necrosis 
factor alpha inhibitor infliximab. Arthritis 
Rheum 2006; 54(12):3782-9 
31. Radstake TR, Svenson M, Eijsbouts AM, van 
den Hoogen FH, Enevold C. van Riel PL et al. 
Formation of antibodies against infliximab 
and adalimumab strongly correlates with 
functional drug levels and clinical responses 
in rheumatoid arthritis. Ann Rheum Dis 
2009; 68(11 ):1739-45. 
32. Svenson M, (jeborek P, Saxne T, Bendtzen 
K. Monitoring patients treated with anti-
TNF-alpha biopharmaceuticals: assessing 
serum infliximab and anti-infliximab 
antibodies. F:heumatology (Oxford) 2007; 
46(12): 1828-34. 
33. Bartelds GM, Krieckaert CL, Nurmohamed 
MT, van Schouwenburg PA, Lems WF, 
Twisk JW et al. Development of antidrug 
antibodies against adalimumab and 
association with disease activity and 
treatment failure during long-term follow-
up. JAMA 2011; 305(14): 1460-8. 
34. Mulleman D, Meric JC, Paintaud G, 
Ducourau E, Magdelaine-Beuzelin C. 
Valat JP et al. lnfliximab concentration 
monitoring improves the control of disease 
activity in rheumatoid arthritis. Arthritis Res 
Ther 2009; 11 (6):R178. 
35. Aarnoutse RIE, Schapiro JM, Boucher CA, 
Hekster YA. Burger DM. Therapeutic drug 
monitoring: an aid to optimising response 
to antiretroviral drugs? Drugs 2003; 
63(8):741-53. 
36. van der M a as A, van den Bemt BJ, Wolbink G, 
van den Hooqen FH, van Riel PL, den Broeder 
AA. Low infl~~imab serum trough levels and 
anti -infliximab antibodies are prevalent in 
rheumatoid arthritis patients treated with 
infliximab in daily clinical practice: results 
of an observational cohort study. BMC 
Musculoskelet Disord 2012; 13:184. 
37. Bendtzen K. Is there a need for 
immunopharmacologic guidance of anti-
tumor necrosis factor therapies? Arthritis 
Rheum 2011; 63(4):867-70. [Ed itoria l] 
38. Krieckaert C, Rispens T, Wolbink G. 
lmmunogenicity of biological therapeutics: 
from assay to patient. Curr Opin Rheumatol 
2012; 24(3):306-11. [Review] 
85 
Chapter 4.2 
39. Krieckaert CL, Nair SC. Nurmohamed MT, 
et al. Evaluating the cost-effectiveness of 
personalised treatment with adalimumab 
using serum drug level and anti-adalimumab 
antibodies in rheumatoid arthritis patients. 
Ann Rheum Dis. 71, P104. 2012. [Abstract) 
40. van Gestel AM, Prevoo ML, Van 't Hof MA, 
van Rijswijk MH, van De Putte LB, van Riel 
PL. Development and validation of the 
European League Against Rheumatism 
response criteria for rheumatoid arthritis. 
Comparison with the preliminary American 
College of Rheumatology and the World 
Health Organization/International League 
Against Rheumatism Criteria. Arthritis 
Rheum 1996; 39(1 ):34-40. 
41 . van der M a as A, Lie E, C hristensen R, C hoy 
E, de Man YA, van Riel PL et al. Construct 
and criterion validity of several proposed 
DAS28-based rheumatoid arthritis flare 
criteria: an OMERACT cohort validation 
study. Ann Rheum Dis 2012; doi: 10.1136/ 
annrheumdis-2012-202281 
42. van den Bemt BJ, den Broeder AA, Wolbink 
GJ, Hekster YA, van Riel PL, Benraad B et 
al. Anti-infliximab antibodies are already 
detectable in most patients with rheumatoid 
arthrit is halfway through an infusioncycle: 
86 
an open-label pharmacokinetic cohort study. 
BMC Musculoskelet Disord 2011 ; 12 :1 2. 
43. Detert J, Bastian H, Listing J, Weiss A, 
Wassenberg S, Liebhaber A et al. Induction 
therapywith adalimumab plus methotrexate 
for 24 weeks followed by methotrexate 
monotherapy up to week 48 versus 
methotrexate therapy alone for DMARD-
naive patients with early rheumatoid 
arthritis: HIT HARD, an investigator-initiated 
study. Ann Rheum Dis 2012; doi:10. 1136/ 
annrheumdis-201 2-201612 
44. van den Bemt BJ. Validation of a precise and 
accurate enzyme-linked immunosorbent 
assay for the bioanalysis of infliximab in 
human serurn . ln: HeksterYA, Van Riel PCLM, 
editors. Opt imizing pharmacotherapy in 
patients with rheumatoid arthritis: An 
individualised approach. Nijmegen: Thesis 
Nijmegen University; 2009. p.61-73. 
45. Rau R, Simianer S, van Riel PL, van De Putte 
LB, Kruger K, Schattenkirchner M et al. 
Rapid alleviation of signs and symptoms 
of rheumatoid arthritis with intravenous 
or subcutaneous administration of 
adalimumab in combination with 








Treatment of rheumatoid arthritis (RA) patients has changed drastically in recent years 
from a gradual step-up approach to a 'hit early, hit hard' strategy combined with 
'tight control' .1•6 Although the latter strategy has proved to be superior to the step up 
approach, it may cause overtreatment in a part of the patients7 :8 This is unwarranted, 
as overtreatment might lead to increase in side effects and costs. This thesis focuses on 
overtreatment with infliximab, which is one of the treatment options in RA. Th is TNF-alpha 
blocker is generally safe and effective in RA treatment, but is also associated with some 
dose related side effects and high costs 9 . 17 Therefore, this thesis aims to examine the 
feasibility of down-titration and discontinuation of infliximab in established RA patients 
in three steps: (1) considering important prerequisites for down-tit ration protocols, (2) 
describing the prevalence of successful down-titration, and finally (3) predicting successful 
discontinuat ion or down-titration by means of t herapeutic drug monitoring (TDM). 
PREREQUISITES FOR DOWN-TITRATION 
For down-titration of infliximab, or any other treatment for that matter, a readily avai lable 
and valid fla re criterion indicating disease worsening, is essential for treatment decisions 
regarding further down-titration or re-i nstating therapy. Preferably, t his is based on a 
measure used to assess disease activity in daily cl inical practice, like the Disease Act ivity 
Score 28 (DAS28), which is a validated composite score for disease activity based on the 
number of tender and swollen joints (of 28 joints), t he Erythrocyte Sedimentation Rate 
(ESR) and pat ient's global assessment of disease activity or general health.18:19 There are 
several DAS28 based flare criteria that have been used in other published studies, however 
none have been validated so far. Thus, it is unclear which criterion performs best and to 
which extent f laring in RA patients is classified accurately. A second issue with using a 
DAS28 based flare criterion in clinical practice is the time-consuming ESR measurement 
that hampers the prerequisite of 'readily available' . 
To start with the lat ter: in search of ways to expedite the ESR measurement, which 
is originally measured according to the Westergren method which takes 60 minutes, 
alternative and more rapid methods for ESR estimation can be considered.20 ESR est imation 
based on extrapolat ing the Westergren ESR after 30 minutes (Starrsed 30-minute mode) 
was found to be a reliable alternative, judged by the small limits of agreement (LoA) and 
a very good intra-class correlation coefficient (ICC). Another alternative method is using 
infrared reading of the dynamics of erythrocytes (Aiifax Roller Test-1TH), which only takes 3 
minutes21-23 Although the time gain is considerable this method has larger LoA, a moderate 
ICC and causes misclassification in 26% of the patients when they are classified as being in 
remission, low, moderate or high disease activity. When disease activity is categorized as low 
and non-low disease activity, as also demonstrated by Levitus et al, misclassification is less 
(between 11-15%)2 4 However, this misclassification is no better t han using the ESR of the 
last visit three months ago, which is of course immediately available. 
Considering the alternative options to expedite the disease activity measurement, 
several can be considered . As already mentioned, the ESR of the previous visit can be used. 
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Besides our data only one other study looked at misclassification due to the use of the 
previous ESR instead of the current ESR and this study reported only 9% misclassification 25 
Although there are some generalizability issues in this study and the used ESR method is 
not exactly described, the main comment is that it does not seem face valid to use the 
previous ESR, since increases in disease activity, and therefore probably also in ESR, are 
to be expected in patients during down-titrating treatment. A second option is using a 
disease activity score without ESR. For example, the DAS28 based on C-reactive protein 
(CRP) can be calculated . Unfortunately, the gain in t ime is only limited compared to using 
the extrapolated ESR (Starrsed 30 minute mode) and the DAS28-CRP has consequent 
lower scores if compared to DAS28 2 6 Another example is disease activity scores not using 
an acute phase reactant as one of its components, like the Clinical Disease Activity Index, 
or patient reported outcomes. Up till now, however, there are no studies available on 
superiority to usual care when using these scores in tight control strategies in daily cli nical 
practice . Additionally, there is a considerable difference between the various scores which 
warrants more research before these scores can be used as a basis for a flare criterion. 27;28 
Finally, patients can be asked to visit the outpatient-clinic a day in advance t o measure the 
ESR. Since this requ ires patients to travel to-and-from the hospital twice we did not consider 
this as an acceptable option. Thus, despite all efforts, no quick and reliable solutions are 
available for this problem. We therefore advocate the use of the Westergren method or 
the extrapolated ESR after 30 minutes as measured in the Starrsed-30 minute-mode. 
Next to readily available, a flare criterion used in down-titration of treatment should 
be validated . Although several DAS28 based flare criteria have been used in published 
studies, no validation was done so far. 29-36 We identified and validated 6 candidate DAS28 
based f lare criteria, and found the criterion meeting most of the predefined hypotheses 
for criterion and construct validity to be: an increase in DAS28> 1.2, or > 0.6 if the 
DAS28~ 3.2 37 Additionally, our data demonstrate that a choice in f lare criterion can be 
made based on requirements for sensitivity and specificity in different clinical setti ngs. 
lt should be noted that the definition for RA f lare published by the OMERACT flare 
group includes both severity but also duration of flare: "A flare is any worsening of disease 
activity that would, if persistent, in most cases lead to initiation or change of therapy; 
and a flare represents a cluster of symptoms of sufficient duration and intensity to requ ire 
initiation, change, or increase in therapy" 38 According to this definition, a flare criterion 
needs to include the duration of worsen ing. This is plausible, since deterioration of disease 
activity can be temporary and subsequent spontaneous improvement can occur without 
intervent ion . Unfortunately, there were no suitable databases allowing inclusion of the 
persistence of flares in the val idation analyses. Contemplating on the probable result of 
such an analysis, a more specific criterion can be expected. To prevent classifying patients 
as having a flare before spontaneous improvement can still occur; we used a second 
measurement after minimally 2 weeks to confirm the flare. 
DAS28 based flare criteria bring about another issue: patients have to actually visit the 
hospital to assess whether there is a flare, because of the mandatory lab t esting and joint 
counts. Especially if prompt out-patient cli nic evaluation is challenging, due to for example 
a waiting list for an appointment or a long travelling distance to the hospital, flares can be 
missed. In evaluating treatment, these flares are ideally included in the decision making as 
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well. Therefore, a role for patient reported flare measurements is of interest in the future. 
Besides the OMERACT flare group, also Bertheloth et al created a self-administered tool 
to evaluate flare. Both questionnaires however have not been validated so far and further 
research on their use in different RA cohorts is needed 39·42 
In va lidating any flare criterion, whether it is DAS28- or patient-reported-based, the 
biggest challenge is the lack of a golden standard for flare. After considering several other 
criteria, including future change in rad iographic damage and functioning, it seems that 
up t ill now patient's judgement and physician's judgement on disease worsening is the 
best possible proxy for a golden standard . We chose to use a transition scale to measure 
this, since it is a sensitive method to determine change with a patient reported outcome 
as opposed to change in visual analogue scales 4 3 
Based on the analyses on the prerequisites for a down-titration protocol, we ultimately 
chose to use a DAS28-based flare criterion calculated with the extrapolated ESR in 30 
minutes. Since treatment decisions on whether the infliximab dose had to be increased or 
not were made with the patient wait ing, a 30 minute time gain was considered valuable 
and the extrapolated ESR had very good results on ICC and LoA. The final flare criterion 
that was used to identify patients as having a flare just prior to infliximab infusion was: an 
increase in DAS28> 1.2, or> 0.6 if the DAS28:?: 3.2 on 2 consecutive visits. 
FEASIBILITY OF SUCCESSFUL DOWN-TITRATION 
AND DISCONTINUATION OF TNF-BLOCKERS 
To prevent overtreatment with drugs leading to (dose-related) side effects and high costs 
the advocated paradigms in RA 'hit early, hit hard' and 'tight control' should be amended 
with 'how low can you go'. In other words: first opt imize the result, and then min imize 
the effort. The feasibility of down-titration and discontinuation of biologies, like amongst 
other infliximab, in RA patients with stable low disease activity and stable t reatment is 
a topic of increasing interest. Evaluating studies on dose reduction or discontinuation 
of TNF-blockers reveal different scenarios in which TNF-blockers are down-titrated or 
discont inued: 1) down titrating higher than registered doses, 2) discontinuing TNF-blockers 
in early RA and MTX na'lve induction cohorts, 3) discontinuation or down-titration (or a 
combinat ion of both) of a TNF-blocker in established RA patients. 
Prevalence of successful down-titration and discontinuation 
The feasibility of down-titrating higher than registered doses of TNF-blockers in RA patients 
has been confirmed for both infliximab and adalimumab some t ime ago29'30 Recently, data 
on successful discontinuation of TNF-blockers in induction cohorts of early RA patients have 
increased. Next to the well -known BeSt trial (Dutch acronym for Behandel Strategieen= 
treatment st rategies), which demonstrated successful infliximab discontinuat ion in about 
half the patients who in itially started with the combination of infliximab and methotrexate, 
recent studies added knowledge to discontinuing TNF-blockers in early RA patients 2 '44-4 7 
One of them is the HIT HARD trial (High Induction Therapy with Anti-Rheumatic Drugs), 
which demonstrated no disease activity deterioration (week 48) after adalimumab and 
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placebo discontinuation (week 24) in both groups (nor in improvement for that matter), 
but did result in less radiographic progression (difference in Sharp/van der Heijde score 
2.6 vs. 6.4, p= 0.03).45 In the OPTIMA trial (Optimal Protocol for Treatment In it iation 
with Methotrexate and Adalimumab) also a high percentage of patients remained having 
low disease activity after discontinuing adalimumab in initial responders46;47 Of course, 
in all induction studies it is to be expected that TNF blockers can be withdrawn in a large 
proportion of patients, as they are responding to the methotrexate that was initiated at 
the same moment. This explains to a large extent the high percentage of patients who can 
stop TNF-blocker treatment. 
The first studies on down-titration or discontinuation of TNF-blockers in the established 
RA patients with stable low disease activity and stable treatment were observational cohort 
studies. They have demonstrated that it is an achievable goal in a large percentage of 
patients. lnfliximab discontinuation has also, in addition to our study, been reported in the 
RRR study (Remission induction by Remicade in RA). In this cohort however a much larger 
percentage of successful discontinuation was described, without increasing functiona l 
impairment or significant radiographic progression of 55% 48 The possible explanat ion 
for this large difference - besides chance - is somewhat elusive: baseline characteristics 
like age, percentage of rheumatoid factor positivity, high DAS28 at infliximab initiation are 
comparable and the used flare criterion in the RRR study is, if anything, a bit more sensit ive. 
One explanation might be the difference in disease duration. median 12 (interquarti le 
ranges 9-18) vs. mean 5.9 (range 0.1 - 38.0), since shorter disease duration has been 
associated with successful discontinuation 49 In our study, the majority of patients could 
down-titrate infliximab without a relevant change in DAS28 and quality of life (QoL) after 
one year follow up, but cessation was possible only in 16%. With regard to ada limumab 
recent observational cohort studies (BRIGHT study and HOI\IOR study) demonstrated 
that 18 and 55% could discontinue adalimumab with patients still having low disease 
activityso;51 Studies on discontinuation of several TNF-blockers also demonstrated that 
between 15-25% could stop without relapse of RA49;52 
Only recently randomised cont rolled trials on discontinuation or down-t itration (or a 
combination) of TNF-blockers in established RA patients have emerged . A small pilot study 
(n= 33) in established RA patients in stable remission treated with adalimumab found that 
33% maintained DAS28< 2.6 after discontinuation opposed to 94% in the continuing 
groups3 In addition, a larger study (n= 138) studying a combination of down-titrat ion 
and discontinuation of adalimumab or etanercept showed that 15% could stop and 67% 
could down-titrate the dose. There was no stat istical difference in DAS28 after 18 months 
between maintaining TNF-blocker versus down-titration or discontinuations4 Trials w ith 
etanercept demonstrated that dose reduction to 25mg/week instead of 50mg/week was 
feasible in 44-79% of the patientss 5-57 
In summary, prevalence of discontinuation or down-titration seems to vary between 
the different contexts: down-titrating higher than registered dose is possible in nearly al l 
patients. discontinuing is feasible in more or less half the patients in inception cohorts 
of early RA patients and discontinuing in established RA patients demonstrates variable 
prevalence between the studies, ranging from 13-55%. The variation in prevalence 
between the different studies in established RA patients is d ifficult to grasp. Possible 
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explanations could be, apart from chance, difference in used flare criterion, patient 
characteristics and maybe study design. Based on studies including down-titrat ion, this is 
feasible in a larger proportion than discontinuation. 
Consequences of down-titration and di sco ntinuation 
The long term goals of down-titration and discontinuation are less side effects and costs, 
while maintaining low disease activity or remission . Fewer side effects, although rationa lly 
to be expected, have not been affirmed so far, and hopefully the larger and longer follow-
up of randomized tria ls can shed some light on this. Effects on cost seem clearer: in 
our cohort study costs were substantially reduced with a reduction of more than 3000 
euros per patient during the down-titration year. When the last 4 months were used as 
representative for following years, the cost reduction was even more. Although it may 
seem obvious that down-titration would reduce cost, the extra out-patient-clinic visits, 
extra medication li ke NSAIDS, corticosteroids or DMARDs and sometimes switch to other 
biologies can also increase direct costs during the down-titrating phase. 
Next to the benefits of down-titration there can also be some undesirable effects. 
First of all, disease activity can increase and flares can occur. If down-titration strate~J i es 
include tight control and sensitive flare criteria, follow up revealed that no significant 
persisting increases in DAS28 were observed s4 Temporary flares are however prevalen t in 
all down-titration and discontinuation studies. Based on our f indings and a small French 
study, flares appear to occur within more or less 3 months after a dose down-t itration step 
or discontinuations2 Other studies however have noted longer mean and median t ime t o 
f lare, up to 6-14 months have been described.48A9:54 
Since flares are associated with increased radiographic proqression, this cou ld also be 
a down-side to down-titrationss Unfortunately, no data were collected on this subject 
in our cohort. In one of the induction studies, continuation of TNF-blocker seemed to 
prevent radiographic progression 45 In a few cohort studies in established RA patients, 
radiographic damage was analysed and no evidence for significant progression compared 
to start was found 48:51 So far no data have been published on r·adiographic progression in 
the randomised controlled trialss3:54:56 Future research should further elucidate this. 
Additionally, since anti-TNF-alpha treatment is associated with a reduced incidence of 
cardiovascular events, discontinuing therapy might abolish this beneficial effect-59:60 Then 
again, whether anti-TNF-alpha therapy it self or minimising the systemic inflammation is 
the cause of the reduced incidence remains to be settled beyond doubt and so far no 
clear evidence is presented to prove the hypothesis that TNF blocking therapy reduces 
cardiovascular events independently of disease activity. 
Finally, TNF-blocker down-titration is by some hypothesized to induce anti-infliximab-
antibody formation, which in its turn is associated with secondary failure or infusion 
related allergic reactions 61 -63 Based on publications on down-titration and discontinuations 
no serious, if any, allergic infusion reactions were observed with re-instating therapy or 
increasing the dose. Up till now, secondary inefficacy seems a minor problem; most studies 
describe response after increasing the dose or resta rting treatment , although in our cohort 
and one of the other studies secondary fai lure was seens2 The exact role of antibodies 
remains unsure however. In our study, 2 of 3 patients with secondary failure had already 
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antibodies at baseli ne and one of them even had antibodies a year before and the last one 
did not have any antibodies (unpublished data). 
In conclusion, since clear benefits have been demonstrated for down-titration and 
discontinuation and major drawbacks, like disease activity increase, secondary ineffectivent?ss, 
radiographic progression and allergic reactions, have not been observed, we would advise 
to down-t itrate the dose of infliximab in RA patients with stable low DAS28. Of course 
research is st ill needed to further clarify the balance between benefits and harms. 
Prediction of successful down-titration and discontinuation 
Useful predictors of successful down-titration could further improve the risk benef it 
ratio of these strategies, since they could on one hand prevent flaring in patients that 
need the current dose of TNF blocking treatment, and on the other hand save t ime-
consuming down-titration in patients who could have directly discontinued biologic 
treatment. Several disease related factors have been identified as being associated w ith 
successful discontinuation, among them low disease activity at baseline, early initiation of 
RA treatment in the disease course, shorter disease duration, less radiographic damage 
at baseline, initial treatment with combination therapy. 48:49:51 :52 The patient and disease 
related factors that were associated in some studies were rheumatoid factor positivity, 
male gender, low levels of immunological abnormality. Other patient and treatment 
characteristics were not associated with successful down-titration or discontinuation, 
surprisingly including concomitant DMARD use. Analysis in our cohort revealed no 
significant or relevant predictive factors. This is probably also due to the small sample size, 
impeding multivariate analyses and increasing confidence intervals for univariate analyses. 
Besides clinical predictors, possible predictors for successful down-titration or 
discontinuation could be residual disease activity, assessed by sensitive imaging techniq ues 
like ultrasonography, MRI or PET. In one long-term study of patients with established RA in 
DMARD-induced remission, the presence of power-Doppler activity predicted future jo int 
damage 64 However a predictive value of ultrasonography for successful discontinuation 
of TNF -blocker could not be confirmed so far.49:52 Future research is needed to further 
explore the value of imaging techniques. 
Predictive value of therapeutic drug monitoring 
Since there is an association between clinical effect and infl1iximab serum trough level 
and anti-infliximab antibodies, the use of therapeutic drug monitoring (TOM) might be 
of aid in predicting whom to down-titrate. To start with, a valid and reliable drug assay is 
available65:66 Additionally, in patients with low DAS28 a large variation in serum trough 
levels and anti -infliximab antibodies is present, with about one-third of the patients with 
low DAS28 having low to non-measurable infliximab trough levels. Finally (anti) infl iximab 
trough level measurements are reliable in patients with stable t reatment and disease. 
Unfortunately our following hypotheses: 1) RA patients with stable low disease activity 
and low to non-measurable serum trough levels, or anti-infliximab antibodies, can stop 
infliximab treatment without deterioration of disease activity, and 2) RA patients with stable 
low disease activity and high trough levels can partly down-titrate without deterioration of 
disease activity were rejected. So far, no other intervention studies have been performed 
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using TOM, so comparison is up till now unattainable. There is one other study examining 
the presumed cost-effectiveness of predicting successfu l discont inuation of ada limumab 
by means of trough levels: a Markov-model is used based on the assumption that trough 
levels are predictive. Our data on infliximab could not confirm this premiseY 
Pondering on possible explanations for the lack of predictive value of infliximab serum 
trough levels, it could be that, since our test measures unbound infliximab, patients with 
low infliximab levels are patients with high TNF-alpha levels. In other words, they might 
consume more infliximab with subsequent lower trough levels. This explanation is however 
not reconcilable with the frequent described positive correlation between infliximab trough 
levels and clinical effect62:65:66:68:69 Apparently the knowledge on the relation between 
TNF-alpha levels and response is still inconclusive and studies a re contradictoryJ0-74 
An explanation for the lack of predictive value of anti-infliximab antibodies for successful 
discontinuat ion could be that not the mean-inhibitory-concent ration (MIC) of infliximab is 
responsible for the effect, but the peak level is. Since the level of anti-infliximab antibodies 
is the resu ltant of antibody formation and (antigen-bound) antibody clearance, the peak 
level of infliximab might be enough to temporarily exceed the ant i-infliximab-ant ibodies 
and to target intra-articular cell lining producing TNF-alpha with subsequent cytotoxic 
effect. Contradictory to this line of reasoning seems that subcutaneous TNF-blockers are 
effective without peak levels. Also, it could be conceived that low infliximab serum levels 
and anti-infliximab antibodies just before the next infusion do not represent low serum 
levels or anti-infliximab antibodies during the majority of the treatment interval. Given 
that patients having anti-infliximab antibodies prior to infusion also have low infliximab 
levels or anti-infliximab antibodies in the middle of the infusion interval, suggesting lack 
of TNF-blocker exposure during most of the interval, this last argument seems un li ke ly 
. 
7° Finally, infliximab could have its effect in a different compartment (such as synovial 
fluid) than serum. This seems very unlikely since infliximab is expected to follow the 
osmotic gradient, assuming that the synovial compartment can be reached due to active 
inflammation with subsequent fenestration. For a definite answer to our questions future 
research has to be awaited. 
IMPLEMENTATION OF DOWN-TITRATION AND DISCONTINUATION 
OF TNF-BLOCKERS IN DAILY CLINICAL PRACTICE 
Since down-titration or discontinuation is feasible in a substantial part of the patients as 
demonstrated for infliximab in this thesis and adalimumab and E?tanercept in other studies, 
we encourage the implementation of the paradigm 'how low can you go'. Nevertheless, 
we recognize that implementing this strategy in daily cl inical practice will be challenging. 
Firstly, changing the physicians' mindset from 'never change a winning team' to 'how low 
can you go' will be difficult. Secondly, if the adherence to the paradigms 'hit early, hit 
hard' and 'tight control' is analysed in registries of RA patients it has to be concluded that 
there sti ll is a lot of progress to be made l 5:76 Adding another paradigm may not improve 
adherence . Finally, feasib ility of implementing 'how low can you go' is partly dependent 
on how well 'tight control' is implemented . Both paradigms need frequent monitoring of 
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disease activity and adjusting therapy when necessary, with the difference being that this 
is either when the goal is not reached or if a flare occurs. Then again, the need to comply 
with quality indicators as described by rheumatology guidelines and current financial 
impulses to reduce costs could stimulate implementation of both strategies. Furthermore, 
with the patient's perspective in mind, there is an obligation to reduce the risk of side 
effects as much as possible given that the disease activity remains low. Therefore at least 
an effort for implementing down-t itration should be considered. 
Contemplating on implementation, we would advise a well-defined protocol so that 
treatment decisions during down-titration are faci litated . In th is manner it is possible 
to include physician assistants or specialized nurses to aid in down-titrating treatment. 
which will limit the burden on outpatient clinic visits to rheumatologists. This protocol 
should include a manual how to dose reduce and how long to wait before a next down-
titration step is initiated. Secondly, as dose reduction is impractical with adalimumab and 
etanercept due to fixed doses per injection we would propose to increase the interval 
between inject ions as also is done in the study by Fautrel et als4 Of note, etanercept could 
of course also be given at 25mg per week, but then further reduction is not possible. 
Thirdly, recommendations on down-titration or discontinuation should be included in 
international guidelines. The Dutch and European gu idelines already have comments 
on the subject; however introducing quality indicators concerning down-titration could 
accelerate implementationn :78 Finally, and maybe more in general, we argue that at each 
outpatient clinic visit changing treatment in RA patients should be considered: if patients 
have reached the goal of low disease activity or remission treatment should be increased 
or switched, and if patients have reached the desired goal it should be examined if the 
same result can be maintained with a lower dose. 
CLINICAL IMPLICATIONS 
The following clinical implication can be derived from this thesis: 
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The use of DAS28 based on ESR measured by automated analyzers can ca use 
considerable misclassification, even though agreement with ESR measured according 
to the Westergren method seems acceptable. Rheumatologists should be aware of 
this misclassification, and preferably only use the ESR according to the Westergren 
method. 
A sensible, feasible, and validated RA flare criterion that can be used in clinical practice 
in patients with low disease activity is: an increase in DAS28 of more than 1 .2, or of 
more than 0.6 if DAS28 is more than or equal to 3.2. 
In different clinical settings, based on sensitivity and specificity, other f lare cr iteria can 
be chosen . Since it is feasible to down-titrate or discontinue infliximab in the majority 
of RA patients with stable low DAS28 and stable treatment with consequently a 
considerable cost reduction without influencing quality of life, rheumatologists should 
consider lowering the dose while monitoring disease activity. 
Down-titration studies should include an induction phase followed with a maintenance 
phase. This allows researchers to draw conclusions on cost-effectiveness in both pha:;es: 
costs are expected to be higher in the first phase due to ext ra outpatient-cl inic visits, 
General discus,sion 
medications and possible work-absenteeism, but lower in the maintenance phase. 
(Anti) infliximab levels are reliable if measured at consecutive visits within stable patients 
and there is considerable variation between RA patients with stable low disease activity. 
Using infliximab trough levels or anti-infliximab antibodies to decide which patients to 
down-titrate or discontinue is not recommended, as this test has no predictive value. 
Risk for al lergic infusion reactions and secondary inefficacy should not be used as an 
argument not to down titrate TNF-blocker treatment. as it is infrequent to non-exist ing 
in current data. 
No clear predictors for successful down-titration or discontinuation are currently 
available and therefore down-titration should be attempted in all RA patients in stable 
low disease activity and treatment to identify those that can discontinue and those 
that do just as well with a lower dose. An essential condition to do this is frequent 
mon itoring of disease activity and adjusting therapy in case of f lare. 
Implementation of the paradigm 'how low can you go' next to 'hit early, hit hard' and 
'tight control should be encouraged. 
FUTURE RESEARCH 
The following suggestions for future research based on this thesis are: 
Identifying and validating other rapid acute phase measurements to optirnize 
outpatient-clinic care for rheumatoid arthritis patients 
Assessing misclassification in the DAS28 due to random or systemic errors in measuring 
the other components 
Validating other DAS28 based flare criteria using the same hypotheses. Criteria could 
also be based on other disease activity measures including CDAI and SDAI 
Further development and validation of patient-reported flare questionnaires to enable 
assessment of flares in between outpatient-clinic visits 
Assessing the effects of down-titration or discontinuation of TNF-blockers on 
radiographic progression, change in functionality and cardiovascular risk 
Studying the feasibility of down-titration and discontinuation of other biologies than 
TNF-blockers 
Confirming or rejecting of the lack of predictive value of serum trough levels of 
biologies in other cohorts and other biologies 
Further research in predictors for successful down-titration and discontinuation of 
TNF-blockers is needed to prevent flares in patient treated with the right dose and to 
prevent t ime consuming down-titration in those who can stop 
The optimal down-titration protocol with regard to time between subsequent interval 
increases should be identified 
Feasibility of down-titration or discontinuation of treatment in other rheumatic 
diseases, like for example psoriatic arthritis or ankylosing spondylitis, could be studied. 
Although this firstly requires further validating of disease activity measures, response 
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Chapter 1 General introduction 
Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic disease that causes a symmetric 
polyarthritis in most patients, w ith subsequent loss of functiona l ability, progressive 
joint destruction and loss of quality of life. Treating RA patients early in the d isease with 
combinations of disease modifying anti -rheumatic drugs (DMARD), glucocorticoids and 
even biologies (hit early and hard) combined with frequent monitoring of disease activity, 
setting a treatment goal and adjusting therapy if the goal is not reached (tight control) is 
more effective than usual care. However, this strategy may lead to overtreatment, which 
is, amongst others, a concern for biologic treatment due to dose-related side effects and 
considerable costs. Down-titration of the dose in patients with stable low disease activity 
could reduce overtreatment. The aim of this thesis is to answer the question whether this 
is feasible in established RA patients treated with infliximab with stable low disease activity. 
Chapter 2 Flare criterion in rheumatoid arthritis 
An important prerequisite for down-titration of infliximab is a valid and readily available f lare 
criterion, indicating disease worsening. Ideally this is based on an instrument used to measure 
disease activity in daily clinical practice and is not t ime consuming, allowing direct treatment 
decisions the moment the patient visits the outpatient clinic. A validated f lare criterion based 
on the widely used DAS28, which is a va lidated composite score based on the number of 
tender and swollen joints (of 28 joints), the Erythrocyte Sedimentation Rate (ESR) and patient's 
global assessment of disease activity or general health, would thus be appealing. 
Chapter 2.1 Misc lassificat ion due to different methods for rapid ESR determination 
One down-side of the DAS28 as a base for the flare criterion is the time consuming ESR 
measurement. Alternative rapid ESR analysers are widely available nowadays and could optimise 
RA care. We compared several rapid ESR analysers w ith the golden standard Westergren 60 
minute method, and found for the ESR measured by the Starrsed 30-minute mode a high 
intraclass-correlation coefficient (ICC) of 0.97 (95% confidence interval (Cl)= 0.96-0.98) and 
narrow limits of agreement (LoA) of -9.4 and 9.7 mm/h. For the Alifax Roller Test-1TH (3 
minutes), acceptable ICC (0.67, 95% Cl= 0.56-0.76) was found, however LoA were large 
(-42 .6 to 33.8). Longitudinally, the Alifax was further analyzed (n= 125) comparing not only 
ESR values but also the effect on DAS28 values. LoA and ICC in DAS28 demonstrated an 
acceptable agreement between the Alifax compared to Westergre•n. However, the percentage 
of DAS28 misclassification between disease activity categories (remission, low, moderate to 
high disease activity) was considerable (26%), and no better than the misclassif ication that 
is present when the ESR from the previous visit was used (22%). Therefore we concluded, 
that ESR measured with Alifax is not preferred in DAS28 calculat ion, but that the 30 minute 
Starsedd mode provides an acceptable alternative with regard to process time. 
Chapter 2.2 Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria 
A flare criterion is necessary in down-titration of treatment to define at which level of 
disease activity worsening the dose should be increased or treatment re-initiated . Six 
DAS28 based flare criteria have been previously published, however none of them has 
been validated thus far. These criteria were 
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1. increase in DAS28> 1 .2, or > 0.6 if DAS28> 5.1; 
2. increase in DAS28> 1.2, or> 0.6 if DAS28~ 3.2; 
3. increase> 0.6 or DAS28> 3.2; 
4. increase in DAS28> 1.2; 
5. DAS28> 3.2; 
6. DAS28> 2.6. 
For this validation study, all proposed criteria were tested against f ive hypotheses 
concerning criterion and construct validity in three different RA patient data bases in 
which flare might occur: 
hypothesis 1: sensitivity and specificity of the flare criterion for patient's judgment on 
disease deterioration should be more than 70%; 
hypothesis 2: equal to hypothesis 1, only physician's judgment; 
hypothesis 3: the difference in proportion of patients in whom DMARD or corticosteroid 
initiation and/or increase occurred should be more than 0.2 between flare and no flare; 
hypothesis 4 : the mean difference in ( -reactive protein (CRP) between patients w ith 
and without flare has to be over 10 mg/1; 
hypothesis 5: no statistical difference in Short Form-36 Mental Health subsc:ale 
change should be present between flaring and non-flaring patients. 
Only criterion 2, which was an increase in DAS28 > 1.2 or> 0.6 if DAS28 ~3.2, fulfil led 
at least 4 out of the 5 hypotheses, which was considered necessary for va lidation. The 
results of this study can facilitate choosing the most appropriate flare criterion in different 
clinical and research settings. 
Chapter 3 Down-titration or discontinuation of inflixi mab in rheumatoid arthrit is 
patients with stable low disease activity and stable treatment 
Since overall data on down-titration or discontinuation of infliximab in established RA 
patients with stable low disease activity are sti ll limited, and the consequences with regard 
to cost-effectiveness are not yet clear, an observational cohort study was carried out to 
describe the cumulative incidence of successful down-titration in daily clinical practice and 
its effect on costs and quality of life (QoL). In all RA patients treated with infl iximab w ith 
stable low DAS28 and stable RA treatment for at least 6 months, the infliximab dose was 
down-titrated with 25% of the original dose (3 mg/kg) every 8--12 weeks without interval 
change until infliximab could be discontinued or a patient flared. After 1 year 16% (95% 
Cl= 6 - 26) of the patients could discontinue infliximab and 45<Vo (95% Cl= 31 - 59) could 
partly down-titrate . The median DAS28 increased slightly from 2.5 (p25-75= 2.0-2.9) 
to 2.8 (2.2- 3.6) (p= 0.002). Some extra glucocorticoids were given (8% of the visits), 
DMARD change was rare. No statistical difference in QoL was observed after one year. 
The mean reduction in costs was considerable, with €3474 (95% Cl= 2457 - 4492) 
per patient during one year. Extrapolating the last four months to the following year 
suggests an even larger reduction in costs. Based on these data, we concluded that in the 
majority of patients with stable low DAS28 and stable treatmPnt. down-titration or even 
discontinuation of infliximab is feasible and results in considerable cost reduction without 
influencing quality of life. 
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Chapter 4 Therapeutic drug monitoring 
There are at least two drawbacks to a dose down-titration strategy as described in the previous 
chapter. First, the occurrence of temporary flares is inevitable in patients who turn out to be 
needing the current dose of the drug. On the other hand, identification of patients in whom 
TNF-blockers can be discontinued takes a lot of time when the dose is gradually reduced, as 
the drug could have been stopped directly. A promising predictor for succesful down-tritration 
or discontinuation of infliximab could be the use of therapeutic drug monitoring (TDM), in 
other words measuring infliximab serum trough levels and anti-infliximab antibodies. 
Chapter 4.1 Variation and reliabil ity of infliximab serum trough levels and anti-infliximab antibodies 
Before TDM was studied for its' predictive value in infliximab down-titration in patients 
with stable low disease activity, we verified in a longitudinal, observational cohort of 1147 
RA patients treated with infliximab for at least 6 months whether a variation in infliximab 
serum trough levels and anti-infliximab antibodies is present in patients with stable low 
DAS28. In these patients 31% (95% Cl= 20-42%) had low(< 1mg/L) and 14% (9 '3 % 
Cl= 5-22) high trough levels (> 5mg/L). Ant i-infliximab antibodies were found in one-
third of the patients with low disease activity. In addition, agreement between repeated 
measurements of infliximab serum trough levels and anti-infliximab-antibodies in stable 
patients with respect to treatment and disease activity was also confirmed . This shows 
that this is a stable marker, and thus increases the chance that these measurements can 
be used as predictor for successful down-titration or discontinuation. 
Since low (and high) infliximab serum trough levels are prevalent in patients with low 
disease activity, and consecutive measurements of serum trough levels and anti-infliximab 
antibodies are reliable in stable patients, we decided to further examine the predictive value of 
TDM in infliximab down-titration in a selected patient group, which is described in chapter 4.2. 
Chapter 4.2 Predictive value of basel ine (anti-) infliximab serum trough levels for successful 
down-titration or discontinuation 
Our hypotheses were that patients with low to non-measurable infliximab trough levels were 
patients who could most likely stop infliximab and patients with high levels would be able to 
reduce the dose. In 51 RA patients described in chapter 3, baseline infliximab serum trough 
level and anti-infliximab antibodies were measured and categorised - based on previous data 
-as low(< 1.0 mg/1), normal (1 .0- 5.0 mg/1) and high(> 5.0mg/l). Sensitivity and specificity of 
low and high trough levels at baseline for predicting successful infliximab discontinuation and 
successful partial down-titration was 50% (95% confidence interval (95% Cl= 16-84) and 56 
(95% Cl= 40-71) for discontinuation and 26% (95% Cl= 10-48) and 82% (95% Cl= 63-94) 
for down-titration respectively. The same analysis was also done for anti-infliximab antibodies 
and cessation, demonstrating sensitivity and specif icity of 13% (95% Cl= 3-53) and 84% 
(95% Cl= 69-93). Perhaps surprisingly, based on these test-characteristics we concluded that 
baseline (anti-)infliximab serum trough levels do not seem useful in prediction of successful 
down-titration or cessation of infliximab in RA patients with stabl+e low disease activity. 
Chapter 5 General discussion 
In the last chapter, the main findings of this thesis are discussed in the context of published 
data, clinical implications and future research . The aim of this thesis was to investigate 
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the feasibil ity of down-titration or discontinuation of infliximab in established RA pat ients 
with stable low disease activity and treatment. As described in chapter 2, the prerequisite 
for down-titration, a readily available and valid flare criterion, was fulfilled. There are on ly 
a few other publications on both prerequisites. Therefore, future research should aim at 
identifying and validating other rapid ESR measurements. In addition, patient reported RA 
flare criteria, which currently are being developed in OMERACT cooperation, should be 
validated. To further improve disease activity guided treatment of patients, assessment of 
misclassification in the DAS28 due to random or systemic errors in measuring the other 
components would also be interesting. 
Down-titration or discontinuation of infliximab is feasible in the majority of establ ished 
RA patients with stable low DAS28 and stable treatment resulting in a considerable cost 
reduction without compromising quality of life. Based on our and other studies, down-
titration seems feasible in a larger proportion than discontinuation. Future research should 
clarify the influence of down-titration or discontinuation of TNF-blockers on radiographic 
progression, functionali ty and cardiovascular risk. Unfortunately, no predictors for successful 
down-titration or discontinuation could be found. Our hypothesis that TDM could be of 
help was rejected. Whether this also applies to serum levels of other biologies has to be 
confirmed yet. Finally, further research is needed to find predictors for successful down-
titration and discontinuation of TNF-blockers to prevent flares in patients already receiving 







Hoofdstuk 1 Algemene inleiding 
Reumato'ide artritis (RA) is een chronische ontstekingsziekte, waarbij de meeste 
patienten een symmetrische gewrichtsontsteking hebben, met verlies van functionaliteit, 
gewrichtsschade en verlies van kwaliteit van leven als gevolg. De huidige behandeling van 
RA bestaat ideaal gesproken uit: 1) zo vroeg mogelijk in het ziekteproces behandelen ('hit 
early'), 2) het combineren van reumaremmers (Disease Modifying Anti-Rheumatic Drugs, 
DMARDs), glucocortico'iden en biologies ('hit hard') en 3) frequent de ziekteactiviteit 
meten, een behandeldoel stellen en therapie aanpassen als het doel niet bereikt is ('tight 
control'). Deze strategie is in meerdere onderzoeken effectiever gebleken dan routine zorg, 
maar kan potentieel leiden tot overbehandeling. Dit geeft problemen bij onder andere 
biologies, waarvan infliximab er een is, door (dosisafhankelijke) bijwerkingen en kosten. 
Afbouwen van de infliximab dosis bij patienten met langdurig stabiele lage ziekteactiviteit 
zou overbehandeling kunnen voorkomen. In dit proefschrift is bekeken of dit haalbaar 
is bij patienten met lang bestaande RA in de dagelijkse klinische praktijk, daarnaast zijn 
verschillende noodzakelijke randvoorwaarden om te kunnen afbouwen onderzocht. 
Hoofdstuk 2 Flare-criterium bij reumato"lde artritis 
Een belangrijke randvoorwaarde voor afbouwstudies is een gevalideerd 'flare' -criterium. Dit 
is een maat om mee vast te stellen of er een dusdanige toename in ziekteact iviteit is dat dosis 
ophogen of medicatie herstarten noodzakelijk is. Ideal iter is dit f ila re-criterium gebaseerd op 
het meetinstrument voor ziekteactiviteit dat al gebruikt wordt in de dagelijkse klinische 
praktijk. Daarnaast moet het f lare-criterium snel beschikbaar zijn, zodat op het moment 
van polikliniekbezoek de arts direct de juiste behandelbeslissin9en kan nemen. De DAS28 
is een veel gebruikte en gevalideerde ziekteactiviteit-score, die bestaat uit een combinatie 
van het aantal pijnlijke en gezwollen gewrichten (van 28 gewrichten), de bezinking (BSE) en 
het oordeel over de ziekte-activiteit (of de algemene gezondheid) van de patient zelf. Een 
flare-criterium gebaseerd op de DAS28 zou daarom voor de hand liggen. 
Hoofdstuk 2.1 
Een nadeel van de DAS28 is dat de bezinking (BSE) veel tijd kost (60 minuten). 
Geautomatiseerde alternatieve bepalingen van de BSE kunnen tijdswinst opleveren. Als de 
BSE gemeten door de Starrsed 30-minuten modus vergeleken wordt met de BSE volgens 
de originele Westergren methode (60 m in) blijken de resultaten qua betrouwbaarheid erg 
goed met een intra class-correlatiecoefficient (I CC) van 0,97 (95°/.o betrouwbaarheidsinterval 
(81)=0,96-0,98) en limits of agreement (LoA) van -9,4 en 9,7 mm/u . Bij vergelijking van 
de Westergren BSE met de Alifax Roller Test-1 TH werd een redelijke betrouwbaarheid 
gevonden als de ICC werd bekeken 0,67 (95% Bl= 0,56-0,76), maar de LoA waren groot 
(-42,6- 33,8). Aangezien een bepaling met de Alifax Roller Test- 1 slechts 3 minuten 
duurt, werd deze verder bekeken in een longitudinale studie (n= 125). Hierbij bleek het 
verschil in DAS28 berekend met 6f de Alifax 6f de Westergren methode relatief klein en 
werd een acceptabele LoA en een ICC gevonden van 0,93 (95% Bl= 0, 71-0,97). Er bleken 
echter veel patienten verkeerd te worden geclassif iceerd als ze waren ingedeeld in de op 
de DAS28 gebaseerde categorieen remissie, lage, matige of hoge ziekteactiviteit (26%). 
Dit percentage was vergelijkbaar met het percentage verkeerd geclassificeerde patienten 
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als de BSE van het vorige bezoek werd gebruikt (22 %). Kortom, bezinking gemeten door 
de Alifax Roller Test-1TH kan beter niet gebruikt worden voor DAS28 berekening, de 
Starrsed 30-minuten modus lijkt een uitstekend alternatief. 
Hoofdstuk 2.2 
Een flare-criterium is nodig bij het afbouwen van infliximab om vast te stellen wanneer 
dosis ophoging of herstarten van medicatie nodig is. Zes op de DAS28 gebaseerde f lare 
criteria zijn beschreven in andere onderzoeken, maar nog niet gevalideerd . Het betrof de 
volgende zes flare criteria: 
1. DAS28 st ijging> 1 ,2, of> 0,6 als DAS28> 5,1; 
2. DAS28 st ijging> 1 ,2, of> 0,6 als DAS28~ 3,2; 
3. DAS28 stijging> 0,6 of DAS28> 3,2; 
4. DAS28 stijging> 1 ,2; 
5. DAS28> 3,2; 
6. DAS28> 2,6. 
Deze criteria zijn getest op vijf hypothesen om criterium en construct validiteit te bepa len 
in drie verschil lende cohorten met RA patienten: 
hypothese 1: de sensitiviteit en specificiteit moeten meer dan 70% zijn ten opzichte 
van het oordeel van de patient over opvlamming van de RA; 
hypothese 2: idem hypothese 1, alleen dan ten opzichte van het oordeel van de arts; 
hypothese 3: het verschil in proportie patienten dat start met. of een dosisophoging 
heeft van een DMARD of corticostero'ld moet meer zijn dan 0,2 tussen de 'flare' groep 
en de niet flare groep; 
hypothese 4: het gemiddelde verschil in C-Reactive Protein (CRP) moet meer zij n dan 
10 mg/1 tussen RA patienten met en zonder een flare; 
hypothese 5: er mag geen statistisch significant verschil in de ShortForm-36 Mental 
Health subschaal zijn tussen flare en geen f lare visites. 
Het enige flare-criterium data an tenminste 4 van de 5 hypotheses voldoet bleek criterium 
2: een DAS28 stijging > 1,2 of> 0,6 als DAS28~ 3,2. Daarnaast kan, doordat alle criteria 
nu op een rij gezet zijn, er in andere klinische situaties of onderzoeken een keuze gemaakt 
worden voor het meest geschikte criterium op basis van de resultaten op de 5 hypothesen. 
Hoofdstuk 3 Afbouwen of stop pen met infliximab? 
Aangezien gegevens over afbouwen of stoppen met TNF-blokkers bij patienten met lang 
bestaande RA nog beperkt zijn en er nog weinig bekend is over de kosteneffectiviteit 
van afbouwen en eventueel stoppen is er in een observationele cohortstud ie gekeken 
naar de prevalentie van succesvol afbouwen of stoppen met infliximab in de dagelijkse 
klin ische praktijk en het effect daarvan op de kosten en kwal iteit van het leven. Bij alle RA 
patienten behandeld met infliximab en een stabiele lage DAS28 en stabiele RA behandeling 
gedurende ten minste 6 maanden, is de infliximab dosis afgebouwd met 25% van de 
oorspronkelijke dosis (3 mg/kg) elke 8-12 weken zonder wijzigingen in het infuusinterval. 
Na 1 jaar bleek dat bij 16% (95% Bl 6 tot en met 26) van de patienten infliximab gestopt 
kon worden en in 45% (95% Bl= 31-59) kon de dosis gedeeltelijk worden verlaagd. De 
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mediane DAS28 was na 1 jaar iets opgelopen van 2,5 (interkwartiel= 2,0-2,9) naar 2,8 
(2,2- 3,6) (p= 0,002) . Tijdens sommige visites zijn er extra glucocortico"lden gegeven (8':Yo), 
DMARD-wijzigingen hebben zich zelden voorgedaan. Na een jaar was er geen statistisch 
significant verschil in kwaliteit van leven vergeleken met daarvoor, maar de kosten waren 
wel aanzienlijk afgenomen met €3474 (95% Bl= 2457-4492) per patient gedurende het 
afbouwjaar. Als de kosten in de stabiele fase van de laatste vier maanden worden bekeken, 
is de kostenreductie per jaar nog veel groter. Op basis hiervan kan er geconcludeerd worden 
dat bij de meeste patienten met lang bestaande RA, stabiele lage DAS28 en stab iele 
RA behandeling, afbouwen of stoppen van infliximab mogelijk is, met een aanzienl ijke 
kostenreductie als gevolg, zonder veranderingen in kwaliteit van het leven. 
Hoofdstuk 4 Therapeutic drug monitoring 
Een nadeel van afbouwen van medicat ie is de mogelijkheid dat de ziekte-activiteit tijdelijk 
opvlamt, daarnaast zou het bij patienten die uiteindelijk blijken te kunnen stoppen rnet 
TNF-blokkers voordelig zijn als er niet eerst een tijdrovend afbouwprogramma doorlopen 
hoeft te worden. Een veelbelovende oplossing om te voorspellen wie wel of niet zou 
kunnen afbouwen of stoppen is Therapeutic Drug Monitoring (TDM): het meten van TNF-
blokker dalspiegels en antilichamen tegen TNF-blokkers. 
Hoofdstuk 4.1 
Voordat TDM getest werd als voorspeller van bij wie infliximab afgebouwd of gestopt kon 
worden, is er eerst gekeken naar het voorkomen van variatie in infliximab da lspiegels en 
anti-infliximab-ant ilichamen in de tijd binnen en tussen patienten. In een longitudinale, 
observationele cohortstudie van RA pat ienten die gedurende minimaal 6 maanden 
behandeld waren met infliximab bleek er inderdaad variat ie te zijn in lage (< 1 mg/1) 
en hoge (> 5mg/l) infliximab dalspiegels en van anti-infliximab antilichamen tussen RA 
patienten met lage ziekteactiviteit: 31% (95% Bl= 20-42%) had een lage dalspiegel en 
14% (95% Bl= 5-22) een hoge. Bij een derde deel van de patienten met lage DAS28 
werden ook anti-infliximab antilichamen gevonden. Daarnaast werd bevestigd dat 
infliximab dalspiegels en anti-infliximab antilichamen erg stabiel en betrouwbaar zijn 
als ze gemeten zijn bij twee opeenvolgende infusen binnen patienten met een stabiele 
DAS28 en stabiele RA behandeling. 
Aangezien er zowel patienten met lage als hoge infliximab spiegels aanwezig zijn onder 
RA patienten met lage ziekteactiviteit, en omdat opeenvolgende metingen in een stabiele 
situatie betrouwbaar zijn, hebben we de voorspellende waarde van TDM verder onderzocht 
in patienten bij wie infliximab werd afgebouwd, zoals beschreven in hoofdstuk 4.2. 
Hoofdstuk 4.2 
Onze hypothesen waren dat 1) een patient met geen of een zeer lage dalspiegel 
vermoedelijk kon stoppen met infliximab (er is namelijk geen medicijn in het bloed te 
vinden en toch is er lage ziekte-activiteit) en 2) dat een patient met een hoge dalspiegel 
waarschijnlijk kon afbouwen. Bij de 51 RA patienten beschreven in hoofdstuk 3 werden 
de infliximab dalspiegels en anti-infliximab antilichamen gemeten bij start van afbouwen. 
Dalspiegels onder 1,0 mg/1 werden geclassificeerd als 'laag', 'normaal' was tussen 1,0-5,0 
mg/1 en hoog was groter dan 5,0 mg/1. Sensitiviteit en specificiteit van lage spiegels 
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voor het voorspellen van succesvol stoppen met infliximab en van hoge spiegels voor 
gedeeltelijk kunnen afbouwen lieten respectievelijk de volgende resultaten zien: 50% 
(95% Bl= 16-84) en 56% (95% Bl= 40-71) en 26% (95% Bl= 10-48) en 82% (9'3% 
Bl= 63-94). Als patienten anti-infliximab antilichamen hadden was de sensit ivi teit voor 
succesvol kunnen stoppen slechts 13% (95% Bl= 3-53) en de specificiteit 84% (9 '3 % 
Bl= 69-93). Op basis van deze test karakteristieken moet voorlopig geconcludeerd worden 
dat TDM niet nuttig is in het vooraf identificeren van RA patienten met stabiele lage 
ziekte-activiteit die kunnen afbouwen of stoppen met infliximab. 
Hoofdstuk 5 Discussie 
In het laatste hoofdstuk zijn de belangrijke bevindingen van dit proefschrift bediscussieerd 
in context van recent gepubliceerd onderzoek, implicaties voor de klinische praktijk en 
toekomstig onderzoek. Het doe I van dit proefschrift was om de haalbaarheid van afbouwen 
of stoppen met infliximab in patienten met lang bestaande RA en stabiele lage ziekte-
activiteit en behandeling te onderzoeken. Zoals beschreven in hoofdstuk 2, werd aan de 
randvoorwaarde voor afbouwen, te weten een snel en valide flare-criterium, voldaan. 
Er is weinig ander onderzoek gepubliceerd over deze randvoorwaarde voor afbouwen. 
Toekomstig onderzoek zou zich dan ook kunnen richten op het identificeren en val ideren 
van andere snelle BSE metingen en het valideren van de patient gerapporteerde flare criteria 
die nu in ontwikkeling zijn. Daarnaast zou evaluatie van misclassificatie door willekeurige 
of systematische fouten in de andere componenten van de DAS28 interessant zijn. 
Afbouwen of stoppen met TNF-blokkers is haalbaar in de meerderheid van de 
patienten met lang bestaande RA en een stabiele lage DAS28 en stabiele behandeling. 
Het heeft een aanzienlijke afname van kosten tot gevolg zonder de kwalite it van het leven 
te be'lnvloeden. Alle data in ogenschouw nemend lijkt afbouwen van TNF-blokkers vaker 
te lukken dan stoppen. Toekomstig onderzoek zou zich moeten richten op de invloed 
van afbouwen of stoppen van TNF-blokkers op belangrijke lange termijn uitkomsten 
zoals radiologische schade, functionaliteit en cardiovasculair risico. Helaas zijn er geen 
voorspellers voor succesvol afbouwen of stoppen gevonden. Onze hypothese dat TDM 
behulpzaam zou kunnen zijn is niet bevestigd. Of dit ook voor spiegels van andere 
biologies geldt zou nog verder onderzocht moeten worden. Tot slot is er meer onderzoek 
nodig om andere voorspellers voor succesvol afbouwen of stoppen van TNF-blokkers te 
vinden. Met name om onnodig opvlammen van de ziekte-activiteit in patienten die al 
behandeld worden met de juiste dosis en tijdrovend afbouwen in patienten die blijken te 








Aatke van der Maas werd op 11 oktober 1976 geboren te Leiden . Zij behaalde haar VWO 
diploma a an het Jacobus College te Enschede in 1995. Daa rna heeft ze Biomedische 
Gezondheidswetenschappen gestudeerd aan de Radboud Universiteit Nijmegen met 
epidemiologie en pathobiologie als specialisatie richtingen . In het laatste jaar heeft ze 
onderzoek gedaan naar de drugsurvival, effectiviteit en toxiciteit van monotherapie TNF-
blokker (adalimumab) vergeleken met methotrexaat in patienten met lang bestaande 
reumato"lde artritis. Na haar afstuderen in 1999 ging ze geneeskunde studeren aan 
dezelfde universiteit, waar ze haar arts examen eind 2003 behaalde. 
Op 1 januari 2004 begon ze de opleiding tot internist in het Maxima Medisch Centrum te 
Veldhoven (opleider dr. A.W.L. van den Wall Bake), met in 2007 het vervolg van die opleiding 
in het Universitair Medisch Centrum St. Radboud te Nijmegen (opleiders prof. dr. J.W.M. van 
der Meer, prof. dr. P.M.J. Stuyt en prof. dr. J. de Graaf). In augustus van 2008 stapte ze 
over naar de opleiding reumatologie in de Sint Maartenskliniek te Nijmegen (opleider Dr. 
M.J.A.M. Franssen) met naast de opleiding een promotietraject waarvan dit proefschrift het 
resultaat is. Haar promotie is begeleid door dr. A.A. den Broede1·, dr. B.J.F. van den Bemt en 
prof. dr. P.L.C.M. van Riel. In 2012 heeft ze het laatste jaar van de opleiding tot reumatoloog 
doorlopen op de afdeling reumatologie in het Universitair Meclisch Centrum St. Radboud 
(opleider prof. dr. P.L.C.M. van Riel) en per 1 februari 2013 is ze werkzaam als reumatoloog 
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In het hele promotie proces is het schrijven toch een van de minder favoriete elementen 
geweest. Laat mij maar nadenken over de onderzoeksopzet. of ploeteren met analyses, of 
het software programma verleiden om een (uiteindelijk toch lelijke) grafiek te maken ... dus 
waar de meesten dit laatste hoofdstuk in een paar minuten wegtikken zit ik al weer veel tijd 
te verdoen. Eigenlijk was een kort en krachtig 'mensen, heel erg bedankt!' de beste versie 
tot nu toe ... maar omdat dit het laatste, en ook waarschijn lijk meest gelezen hoofdstuk zal 
zijn, wil ik er toch wat meer in stoppen dan alleen een kernachtige boodschap. 
lk heb eens nagedacht over het hele promotietraject, en heb eigenlijk voor mezelf een 
aantal essentiele elementen weten te identificeren die mogelijk hebben gemaakt dat dit 
boekje er is gekomen. 
Het begint natuurlijk bij een onberispelijke opvoeding ... en schatten van broertje! 
Lieve mama en Rob, papa en Hanneke, ik vind jull ie schatten! Heel fijn dat ik op zo veel 
verschillende manieren zo veel steun heb gehad bij mijn opleidingen (het hield maar niet 
op, he). Lieve maminka, heel fijn dat je m'n spell ingcheckster wilde zijn. Pieter en Minko, 
jullie zijn de beste broers ooit! lk hoop dat jullie door middel van relativerende en licht 
sarcastische opmerkingen mij bij gaan staan bij de verdediging van dit geheel. Sandra en 
Maxi me, wat heerlijk dat jullie mijn schoonzusje en nichtje zijn! 
Natuurlijk waren de lage en middelbare school nodig om biomedische 
gezondheidswetenschappen te studeren. Maar een aantal super vriendinnen waren veel 
essentieler. Vriendinnen die onder andere: 
1. meereisden naar welk ver oord dan ook en levensmotto's hebben als 'het leven is een 
giraffennek', 
2. ook ongetraind de 4daagse wilden lopen, StoM leuk vonden en in Frankrijk rose zopen, 
3. konden Western blotten, mannen voor me versierden op m'n verjaardag en hoge 
pieken en diepe dalen overwonnen. 
Maar die vooral nog steeds alles in het leven met mij delen en goede schouders hebben 
om op uit te huilen van de lach. Anke, Femke en Manon: ik ben super gelukk ig meta l zo 
lang zulke leuke en lieve vriendinnen als jullie! 
Ook een briljant studentenhuis bleek noodzakel ij k; hier is een goede immuniteit tegen 
vieze grapjes op het to ilet, katers na uit de hand gelopen avondmaaltijden, bbq's op 
dakterrassen gekweekt. Bovendien kon er een obscure voiiE?ybal techniek ontwikkeld 
worden en zijn Moederdag en Zomerfeesten gezamenlijke passies geworden. Michie l, 
Plien, Gert-Jan, Henny, Clau, Bram, ik ben al weer aan het aftellen tot de volgende beren-
shoot-out! Heel leuk dat j ij er ook bij was dit jaar, Brenda. En ook de rest van JC 10 
(Wencke, Stein, Bianca, Maarten, Linda, en a lie anderen): ik ben op jullie! 
Na het afronden van biomedische gezondheidswetenschappen bleek de sluiproute 
naar geneeskunde erg handig om vaardigheden als lompe-zwartgallige-grappen-maken 
en proberen-dokter-te-zijn verder eigen te maken. Hierbij blekE?n er goede rolmodellen in 
mij n co-groep te zitten . In het bijzonder Jiske: beste Sinterklaas ooit en grootmeesteres 
(nee, geen leren pakje en een zweep) in lompe grappen. Ook Jeannemieke: wat goed dat 
na BGW en GNK er ook nog coschappen volgden zodat ook ik je kon leren kennen. 
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En uiteindelijk werden deze ervaringen verder aangevuld in Veldhoven met de 
vaardigheden 'lekker-uit-eten-gaan', 'Ardennen-onveilig-maken' en 'het-opdoen-van 
absurde-ziekenhuis-verhalen-voor-op-welke-verjaardag-dan-ook'. MMC de gekste ! 
Yvette, ik blijf heel graag vasthouden aan m'n huisvriendin privileges bij jou, Marc en nu 
Stijn. lk hoop op heel veel gezelligheid! Esme, wanneer gaan we weer op fietsvakantie;), 
ik kan wel weer een kluifje gebruiken! 
Bij de vervolg opleiding in het Radboud waren er voldoende eigenschappen aanwezig 
om echt verder met onderzoek te gaan. Het kwam goed uit dat Tanya een plekje bij 
de reumatologie voor me afstond, maar daarnaast ook voor de broodnodige lol in het 
Radboud zorgde. Tijdens het promotie traject bleek de saxofoon trouwens een leuke 
af leiding en daar ontdekte ik dan weer Lonneke om ook mee de wereld rond te reizen. 
Daarmee waren de basisingredienten om te kunnen promoveren aanwezig en 
komen we bij de vita le promovendusbehoefte: heel goede begeleiding en een heerl ijke 
promotieplek! 
Even wat over de begeleiding, allereerst Alfons: een zeer enthousiaste, inspirerende en 
af en toe te snelle begeleider die onderzoek tot hoog niveau en tempo hielp. Hij bracht 
ook nog eens inzicht in muziek, irrationaliteit, sport, maar als hij samen met Bart was 
kon het neigen naar op Olympisch niveau pingpongen met argumenten. Alfons, zonder 
jou had ik het niet in deze korte tijd kunnen doen, had ik niet zo vaak heel hard kunnen 
lachen en had ik niet zoveel goede gesprekken gehad! Je hebt tijdens mijn promotie 
traject heel veel meegemaakt en desondanks kon ik al mijn vraqen bij je kwijt. lk hoop dat 
we nog heel lang samen kunnen blijven werken. 
Dan Bart: ook al heel enthousiast! Verder een bron aan nuttige kennis over therapeutic 
drug monitoring en andere apothekers w ijsheid. Hij danst graag (handig bij lege 
dansvloeren tijdens promotiefeestjes) en bleek een engelengecluld te hebben als het gaat 
om open neer naar de 44• verdieping gaan vanwege beschonk·~n buitensluit ing .. . en ook 
hij was soms wat sneller dan ik kon volgen. Bart, ik ben ook heE~I erg in mijn nopjes dat we 
nu sa men Noortje begeleiden en heel erg bedankt voor al je hulp! 
En natuurlijk promotor Piet: hij zorgde voor nieuwe richtingen en ideeen, stuurde 
inhoudelijk bij waar nodig en had goede feedback. Verder was hij in het laatste jaar ook 
nog verantwoordelijk voor de afronding van mijn opleiding. Piet, heel erg bedankt! 
Dan de promotieplek : de Sint Maartensklin iek! Frank, je laat het onderzoek in het 
reumacentrum bloeien . lk ben je erg dankbaar voor de mogelijkheden die je voor me hebt 
gecreeerd en nog steeds creeert. Verder waren zijn creatieve eigen spreekwoorden op lastige 
momenten een enorme steun in de rug . De staf reumatologie zorgde voor een heel leuke 
en leerzame tijd: Agnes, Annemiek, Dirk-jan, Elien (eigenlijk ook mede RIO), Esther, Hans, 
Hatice, Henk (nevenfunct ie: tijdig lunchtijd aangeven), Joost (MMC de gekste!), Karen (veel 
gezelligheid en snoep bij inspiratiegebrek), Maartje, Marcel (ook mijn opleider), Maurice, 
Regina en Vincent Uazzexpert). Aanvullend zorgden Marcel (Fiendrie, Fledder, Lenfrie of hoe 
heet die dokter ook maar weer), Twan (Tonnie Martins voor intimi), Iris (tolereren van fase 2), 
Calin (zelf ook doormaken van fase 2), Anne en Jos (cafe) voor de noodzakelijke afleiding. 
De andere onderzoekers hielpen door goede feedback en advies bij de reumaclub en 
het JOO, maar vooral door veellol bij de schrijfdagen en reumaf,~esten. Heel belangrij k was 
Gijs, als grootleverancier van zwart goud, karmeliet en in het bijzonder gezelligheid ! Maar 
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ook heel erg bedankt voor het toelaten van mijn lay-out jatwerk. Hopelijk tot snel weer 
in de maartenskliniek. Ook Victor ging weleens mee om er eentje weg te 'smurfen'. En 
Chantal en Noortje nemen nu het promovendus stokje over en laten zien hoe onderzoek 
doen werkelijk moet. Els van den Ende, Wietske Kievit, Jaap Fransen, Gert-Jan Wolbink 
en Juliette van Eerd hielpen met inhoudelijke begeleiding bij verschillende artike len en 
onderzoeksvoorstellen . Thasia Woodworth and Elisabeth Lie flared up the inspiration. 
Meer dan een jaar lang werd ik iedere ochtend 'opgevangen' door het ambulant reuma 
centrum: Anja, Ans, Els, lngrid, Jessica, Joyce, Miranda, Petra, Susan (nu ook gezellig in de 
staf natuurlijk) en Yvette bedankt voor al jullie hulp! Ook had de afdeling fa rmacie in de 
SMK veel geduld met het leveren van de infl iximab. Daarnaast zorgden de polikl iniek, het 
secretariaat (Dol inda in het bijzonder, ook voor wat je nu allemaal nog voor me doet), het 
archief en het laboratorium van de Maartenskliniek (vooral Leo, Ester en Tinie) en Sanquin 
voor de noodzakelijke ondersteuning . Freek en Nathalie voerden de data in en Rene en 
Lotte pipetteerden er op Ios. Ook al deze hulp was essentieel 
En dan in de laatste fase van mijn promot ie traject werd nog extra mooie mankracht in 
gezet, daar ontbrak het daarvoor nog aan. Als het aan Robert lag had ik wel een originele 
kaft gehad . .. Lief, khouvje! 
Mensen, heel erg bedankt! 
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